

This is a paper for discussion. It does not represent the views of the Committee and must not be quoted, cited or reproduced.

MUT/2020/16

**COMMITTEE ON MUTAGENICITY OF CHEMICALS IN FOOD, CONSUMER
PRODUCTS AND THE ENVIRONMENT (COM)**

**GUIDANCE ON A STRATEGY FOR GENOTOXICITY TESTING OF
CHEMICALS**

Continued consideration and comments of the updated COM 'Guidance document on a strategy for genotoxicity testing of chemicals'.

Members are asked to complete review of this latest draft as attached and consider the following questions:

1. Could members advise their opinion in answer to each of the remaining comments received from DK and GJ.
2. Can this document be published as COM Guidance?

**Secretariat
November 2020**

GUIDANCE ON A STRATEGY FOR GENOTOXICITY TESTING OF CHEMICALS

Contents

EXECUTIVE SUMMARY	3
I. PREFACE	5
II. INTRODUCTION	7
III. SIGNIFICANCE OF CHEMICAL-INDUCED MUTATION FOR HUMAN HEALTH	8
IV. GENERAL PRINCIPLES OF TESTING STRATEGY	9
V. GENOTOXICITY TESTING STRATEGY.....	10
STAGE 0: PRELIMINARY CONSIDERATIONS PRIOR TO GENOTOXICITY TESTING.....	11
STAGE 1: IN VITRO GENOTOXICITY TESTING	12
DISCUSSION OF STAGE 1 TESTS- GENERAL ASPECTS	15
DISCUSSION OF STAGE 1 STRATEGY: SPECIFIC CORE TESTS	19
DISCUSSION STAGE 1: NON-CORE TESTS.....	23
SUMMARY STAGE 1 (<i>IN VITRO</i> GENOTOXICITY TESTING)	25
STAGE 2: <i>IN VIVO</i> GENOTOXICITY TESTS	26
DISCUSSION OF STAGE 2 INITIAL TESTING STRATEGY - GENERAL ASPECTS.....	31
DISCUSSION OF STAGE 2 - RECOMMENDED <i>IN VIVO</i> GENOTOXICITY TESTS	32
DISCUSSION OF STAGE 2-SUPPLEMENTARY TESTS.....	35
SUMMARY STAGE 2 (<i>IN VIVO</i> GENOTOXICITY TESTING)	38
POSSIBLE FUTURE DEVELOPMENTS	39
REFERENCES	41
GLOSSARY	58
ANNEX 1	67

GUIDANCE ON A STRATEGY FOR GENOTOXICITY TESTING OF CHEMICALS.

Executive Summary

1. The Committee on Mutagenicity of Chemicals in Food, Consumer Products and the Environment (COM) has a remit to provide UK Government Departments and Agencies with advice on the most suitable approaches to testing chemical substances for genotoxicity. The COM published guidance in 1981, 1989, 2000 and again in 2011. This document incorporates some significant changes and reports the COM views regarding the most appropriate strategy for genotoxicity testing (Figure 1) reached in 2020, bringing the guidance document up to date.

2. It should be noted that in this updated guidance, several key areas have been identified [RB1] as potentially requiring frequent updating, due to their fast-moving nature. To facilitate such updates, standalone documents have been prepared outlining the currently available status of the use of Quantitative Structure Activity Relationship (QSAR) modelling (30 - 31) and testing strategies for germ cell mutagens (paras 91 - 94), both of which were included in the previous version of the guidance document. In addition, standalone documents have been prepared detailing the use of 3D tissue models for genotoxicity testing and test guidance strategies for manufactured nanomaterials. Both of these areas were not included in the previous version of the guidance document and are now briefly detailed in paras 28 and 37 respectively.

3. The COM recommends a staged approach to testing:

- **Stage 0** consists of preliminary considerations which include physico-chemical properties of the test chemical substance, Structure Activity Relationships (SAR), and information from screening tests¹. However, data from SAR and screening tests should not overrule test data from adequately designed and conducted genotoxicity tests.
- **Stage 1** consists of *in vitro* genotoxicity tests. The COM recommends a core-test battery of the Ames test combined with the *in vitro* micronucleus test. This combination provides information on three types of genetic damage for which data are required (namely, gene mutation, chromosomal damage and aneuploidy) and gives appropriate sensitivity to detect chemical genotoxins. As also supported by the OECD, the COM consider that there is no need to independently replicate adequately designed and conducted core *in vitro* tests

¹ Note that the terms 'test' and 'assay' are used interchangeably throughout the document to reflect naming conventions.

which are either clearly negative or clearly positive. The strategy document also considers the contribution that can be made by a number of non-core *in vitro* tests.

- **Stage 2** consists of *in vivo* genotoxicity tests. A case-by-case strategy should be developed to answer one or more of the following specific queries;

- 1) Investigation of genotoxic end point(s) identified in Stage 1,
- 2) Investigation of genotoxicity in tumour target tissue(s),
- 3) Investigation of potential for germ cell genotoxicity,
- 4) Investigation of *in vivo* genotoxicity for chemicals which were negative in Stage 1 but where there is high or moderate and prolonged exposure,
- 5) Investigation of genotoxicity in site of contact tissues.

4. The core tests in Stage 2 are the rodent micronucleus/chromosome aberration assays for aneuploidy and clastogenicity, the transgenic rodent gene mutation assay and the rodent [alkaline](#) comet assay for DNA damage.

5. Usually, negative results obtained in a carefully selected *in vivo* test (possibly studying more than one endpoint and tissue) will be sufficient to address positive results found *in vitro*. However, a further test(s) may be needed if some of the genotoxic effects seen in Stage 1 *in vitro* tests had not been adequately studied *in vivo* (e.g. the chemical affects multiple mutagenic end-points), or other aspects of the genotoxic potential of the chemical had not been fully resolved (e.g. [a human metabolite is identified that is not formed, or only in small amounts, in rodents, or](#) in the case where an investigation of heritable effects was required). The strategy document also considers the contribution that can be made by a number of non-core *in vivo* tests. In most instances information from core *in vivo* tests is sufficient to evaluate the *in vivo* genotoxicity of chemical substances. A supplementary *in vivo* test strategy can provide additional information on a case-by-case basis, to investigate aspects such as further characterisation of germ cell genotoxicity, and DNA adduct data which can provide information to elucidate the mode of genotoxic action of carcinogenic chemicals.

I. Preface

6. The COM is an independent expert advisory committee whose members are appointed by the secretary of state for health and social care and the chair of the Food Standards Agency (FSA) following an appointments exercise involving public advertisement. Members serve in their own capacity as independent experts and observe a published code of practice including principles relating to the declaration of possible conflicting interests.

7. The remit of the COM is to advise any UK government departments and agencies with an interest in the safety of chemicals across various sectors on the human health aspects of the mutagenicity and genotoxicity of chemicals (these terms are defined for the purposes of this guidance document in paragraphs 9 - 10 below). The Secretariat is provided by Public Health England (PHE), who lead, and the FSA. Other government departments with an interest provide assessors to the COM; these are specifically from the Department of Health and Social Care (DHSC), the Department of Environment, Food and Rural Affairs (Defra), the Chemicals Regulation Division (CRD) of the Health and Safety Executive (HSE) (responsible for legislation regulating chemicals, pesticides, biocides and detergents), the Environment Agency (EA), the Veterinary Medicines Directorate (VMD; a Defra agency responsible for the licensing of veterinary drugs) and the Medicines and Healthcare products Regulatory Agency (MHRA; a DHSC agency responsible for the licensing of human medicines). In addition, there are assessors from the Scottish Government, the Welsh Assembly Government and the Northern Ireland Assembly.

8. The role of the COM is advisory. It has no regulatory status, although its advice may be provided to a body that does have such a role (e.g. HSE CRD for occupational aspects and for pesticides etc). Its remit is to advise on the human health aspects of the genotoxicity of chemicals, and this may involve advice on a specific chemical, and also on testing strategies and research. This guidance document focuses on testing strategies for chemicals for which there are no available genotoxicity data. Separate guidance on a strategy for the genotoxicity testing and mutagenic hazard assessment of chemicals with inadequate genotoxicity data was published in 2011 (https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/315802/strategy_for_chemicals_with_inadequate_genotoxicity_data.pdf). Throughout this guidance the COM has referred to the genotoxicity testing of chemical(s) which refers to a specified chemical or material, including any additive necessary to preserve its stability and any impurity deriving from the process used.

DRAFT DOCUMENT FOR DISCUSSION

The COM usually provides advice on a specific chemical which can be equated to a single chemical or compound. Provision of advice on radiation aspects is not within the scope of the COM.

9. The COM also has a general remit to advise on important general principles or new scientific discoveries in connection with potential mutagenic and genotoxic hazards (inherent properties of chemicals) or risk (the likelihood of mutagenic or genotoxic effects occurring after a given exposure to a chemical) and to present recommendations for genotoxicity testing. In practice the bulk of the work of the COM relates to assessing genotoxicity tests and providing advice on the genotoxic hazard of chemicals.

10. In the context of testing strategies, the COM first published guidelines for the testing of chemicals for mutagenicity in 1981, and these were revised in 1989 and 2000 (DOH, 2000). These provided guidance to the relevant government departments and agencies on best practice for testing at those times. The rationale developed by COM in 2000, particularly in relation to the testing of all potential mutagenic endpoints, was adopted by the International Workshops on Genotoxicity Testing (IWGT) Muller et al., 2003. The need for guidance to be periodically updated, to reflect advances in development and validation of methods, was recognised and substantially revised guidance was published in 2011 (DOH, 2011). Testing strategies, the same or similar to those outlined in the 2011 COM guidance, have been adopted by some regulatory bodies, including the European Food Safety Authority (EFSA) (EFSA, 2017) and included in the notes on Guidance from the Scientific Committee on Consumer Safety (SCCS) (SCCS, 2016) and in the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) regulation (ECHA, 2017).

11. A further revision of the guidance has been undertaken. This version (COM, 2020) of the guidance outlines the strategy that COM consider to be the most scientifically appropriate given available methods, and recognises the need to avoid the use of live animals where practical and validated alternative methods are available. The COM believes that the approach outlined presents an overview of the core principles of genotoxicity testing and will remain valid for several years. It is acknowledged that existing national or international testing strategies will be at different stages of review and hence inconsistencies are expected. The COM guidance is not intended to supersede or replace existing national or international sector-specific genotoxicity testing strategies (e.g. those recommended for pharmaceuticals by the International Conference on Harmonisation of Technical Requirements for Registration

of Pharmaceuticals for Human Use (ICH) (ICH, 2011), for chemicals assessed under REACH Regulations (EC1906/2006) (ECHA, 2017), or by EFSA (EFSA, 2011).

II. Introduction

12. The COM last published guidance on a strategy for the testing of chemicals for mutagenic potential in 2011 (DOH, 2011). The guidance outlined in 2011 was based on the development of new approaches to identifying genotoxic hazards *in vitro* including new approaches to identify misleading positive results and evaluate target organ genotoxicity *in vivo*. There is also a need for a testing strategy which can encompass chemicals such as cosmetics where no animal tests are permitted under European Union (EU) law. It is the objective of this paper to set out a scientifically valid testing strategy comprising those methods which the COM believe to be the most informative with regards to the detection of genotoxic hazard and (when possible) are well validated. There is no discussion of methods which experience has shown to be suboptimal in determining genotoxicity. Details of methodologies are not given since they are provided in the Organisation for Economic Cooperation and Development (OECD) test guidelines, the EU Test Methods Regulation (EC 440/2008) and the IWGT guidance.

13. The genome can be damaged in a variety of ways either spontaneously or from exposure to genotoxic agents. The term “mutagenic” refers to the ability of a chemical to induce a permanent change in the amount or structure of the genetic material of an organism, which may result in an heritable change in the characteristics of the organism. Chemicals inducing mutations are referred to as mutagens (they are mutagenic). These alterations may involve individual genes, blocks of genes, or whole chromosomes. Mutations involving single genes may be a consequence of effects on single DNA bases (point mutations) or of larger changes, including deletions and rearrangements of DNA. The potential to induce mutation is measured in test systems that detect a broader range of genetic changes than simply mutation – they measure genotoxicity. Mutagenicity is accepted as a key event in carcinogenicity. Epigenetic changes, that could also be heritable, fall outside the scope of this guidance.

14. Genotoxicity refers to interaction with, or damage to, DNA and/or other cellular components which regulate the fidelity of the genome. It is a broad term that, as well as mutation, includes damage to DNA such as the production of DNA adducts, by the chemical itself or its metabolites. Cells have the capacity to protect themselves from such potentially lethal or mutagenic genotoxic effects by many repair processes and therefore many genotoxic events do not become evident as mutations. However, the

capacity to damage the genome (genotoxicity) is an indicator of potential mutagenicity. Thus, some methods that measure genotoxicity do not provide direct evidence of heritable mutation.

15. The objective of genotoxicity testing is to exclude or identify potential hazards to humans and, for those chemicals that are positive, to aid in the elucidation of the mode of action (MoA). This guidance therefore presents a strategy for genotoxicity testing since this term encompasses all the assays included in the strategy. Consequently, it is important to generate information on three types of genetic damage, namely gene mutation, changes to chromosome structure (i.e. clastogenicity) and number (i.e. aneuploidy), to provide comprehensive coverage of the mutagenic potential of a chemical.

16. The COM reaffirms its view, published in 1989, 2000 and 2011, that there is currently no single validated assay that can provide comprehensive information on all three types of genetic damage and thus it is necessary to subject a given test chemical to several different assays. The range of assays discussed in this document include those using prokaryotes (bacteria) and mammalian cells *in vitro*, and whole mammals, where effects in a wide range of target organs including germ cells can be measured. Assays may be classified on the basis of genetic end-points (e.g. gene mutation, clastogenicity, aneugenicity and tests for DNA damage) or by consideration of the different phylogenetic levels (e.g. bacteria, and mammalian cells) represented and also in mammals by the tissues or target organs studied.

III Significance of Chemical-Induced Mutation for Human Health

17. A mutation in the germ cells of sexually-reproducing organisms may be transmitted to the offspring, whereas a mutation that occurs in somatic cells may be transferred only to descendant daughter cells. Mutagenic chemicals may present a hazard to health since exposure to a mutagen carries the risk of inducing germ-line mutations, with the possibility of inherited disorders, and the risk of somatic mutations including those leading to cancer.

18. A separate statement discussing the significance of chemical-induced mutation to human health was published in 2012:

(<https://www.gov.uk/government/publications/the-significance-of-chemical-induced-mutation-for-human-health>).

IV. General Principles of Testing Strategy

19. The COM recommends a two-stage testing strategy (Stages 1 and 2) for the detection of the genotoxic hazard of chemicals which can be supported by appropriate preliminary screening tests and/or *in silico* data (Stage 0).

20. Initial testing for genotoxic potential in Stage 1 is based upon two core *in vitro* tests that are chosen to provide information on gene mutation, clastogenicity and aneuploidy, with case-by-case additional testing and investigation depending on the results of these initial genotoxicity tests. All *in vitro* tests should be designed to provide the best chance of detecting potential activity, with respect to (a) the exogenous metabolic activation system (S9 - see glossary); (b) the ability of the compound or its metabolite(s) to reach the target DNA and/or targets such as the cell division apparatus, and; (c) the ability of the genetic test system to detect the given type of genotoxic event. Where international guidelines are available, the assays should be carried out to conform to those internationally recognised protocols^{[DK3][RB4]} e.g. as published by the OECD, the IWGT and in the EU test methods Regulation (EC 440/2008). The same approach to testing can be used for chemicals where *in vivo* genotoxicity testing is not permitted (e.g. cosmetics). Investigations regarding MoA are important to derive conclusions on biological relevance of *in vitro* genotoxicity test results, to aid in overall risk assessment^[RB5], and to inform on the strategy for *in vivo* tests. This is of particular importance for those chemicals where no *in vivo* genotoxicity testing is permitted.

21. For most chemicals, results from the two Stage 1 core tests should be sufficient to reach a conclusion on the presence or absence of mutagenic potential. However, in some instances, even when Stage 1 tests are negative, regulatory authorities may require consideration of the need for *in vivo* Stage 2 testing particularly where exposure is considered to be high, or moderate and prolonged (e.g. most human medicines), or where there is a chemical class precedent (i.e. structural relationship) of positive *in vivo* genotoxicity data. Guidance on the level of exposure which equates to high, moderate or prolonged is beyond the remit of the COM.

22. Stage 2 consists of a number of *in vivo* tests designed to investigate whether *in vitro* genotoxic activity including specific end-points identified by *in vitro* tests can be expressed in the whole animal. This may also include assays for specific target organs (e.g. rodent tumours detected in carcinogenicity bioassays) or in germ cells. Few chemicals are active only *in vivo* and in such cases this may be due to a number of factors such as metabolic differences, the influence of gut flora, higher exposures *in*

vivo compared to *in vitro*, pharmacological (e.g. folate depletion or receptor kinase inhibition) and extreme physiological effects (Tweats et al, 2007b).

23. There is currently no single *in vivo* test which can assay all three types of genetic damage (Thybaud et al., 2007) and thus a strategy for Stage 2 has to be designed based on the nature of genotoxic effects identified in Stage 1 and the possibility that genotoxic activity will only be expressed *in vivo* as discussed above. However, consideration should be given to the possibility of evaluating different genotoxicity endpoints in a single set of test animals.

24. There should be a clear strategy for planning tests within each stage and for progressing from Stage 1 to Stage 2. Clear statements can be made regarding the initial *in vitro* tests to be used in Stage 1 as these methods have been well studied, whereas the strategy for Stage 2 is more complex and, if not a specific regulatory requirement, needs to be developed on a case-by-case basis.

25. Under the strategy recommended by COM, the use of animals in genotoxicity testing is primarily required when it is necessary to investigate whether genotoxic activity detected in Stage 1 *in vitro* is reproduced *in vivo*, to study target organ genotoxicity (for example involvement of genotoxicity in rodent tumours) and to evaluate the potential for heritable mutagenic effects. Genotoxicity testing using animals, when required by guidance, should be carried out when there is no suitable alternative, and the minimum number of animals should be used, consistent with obtaining valid results. If feasible, studies can be conducted as an adjunct to single or repeat dose toxicity studies. The COM supports current and future developments to replace, refine or reduce the need for animals, consistent with the principles of the 3Rs².

V Genotoxicity Testing Strategy

26. The COM guidance provides a strategy for testing chemicals where no genotoxicity data are available. Test chemicals may also contain impurities at varying levels which may exhibit genotoxic activity. Separate guidance on the genotoxicity assessment of impurities is available at <https://www.gov.uk/government/publications/genotoxicity-assessment-of-impurities-in-chemical-substances>. The assessment and control of genotoxic impurities is the subject of an ICH Guideline (M7) [DK6][RB7] (http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Mul

² <https://www.nc3rs.org.uk/the-3rs>

tidisciplinary/M7/M7_Step_4.pdf) and ICH M7(R1) (http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Multidisciplinary/M7/M7_R1_Addendum_Step_4_31Mar2017.pdf), and a Question and Answer document (<https://www.ema.europa.eu/en/ich-m7-assessment-control-dna-reactive-mutagenic-impurities-pharmaceuticals-limit-potential>).

27. The strategy recommended in the following sections is concerned with testing for genotoxic activity of chemicals and does not specifically address complex mixtures of chemicals.

Stage 0: Preliminary Considerations Prior to Genotoxicity Testing

28. The intrinsic chemical and toxicological properties of the test chemical must be considered before devising the genotoxicity testing programme. Manufactured nanomaterials present particular considerations with regards to genotoxicity testing and these are discussed in a separate document 'Test Guidance Strategies for Genotoxicity Testing of Manufactured nanomaterials' (COM, 202x).

Physico-chemical and Toxicological Properties

29. The physico-chemical properties of the test chemical (for example, acid dissociation constant (pKa), partition coefficient, solubility, volatility and stability in, and potential reactions with, solvents/vehicles) and its purity can affect the ease of conduct and results of *in vitro* tests. For example, the tolerance of cells to acidic chemicals can be enhanced by neutralisation but this may affect the inherent reactivity of chemicals with DNA (Hiramoto et al., 1997). Potential reactions of the test chemical with solvent/vehicle should also be considered (e.g. cisplatin reacts with dimethyl sulfoxide (DMSO)) (Fischer et al., 2008). Alternatively, low solubility may limit the feasibility of undertaking some or all of the *in vitro* mutagenicity tests recommended in this strategy. The potential for auto-oxidation of the test chemical in the culture medium can also affect the outcome of *in vitro* genotoxicity tests (Long et al., 2007). It is noteworthy that the toxic properties of test chemicals, such as target organ effects, or irritancy/corrosivity in contact with skin or mucous membranes and their toxicokinetics and metabolism will influence the choice of route of administration and the highest dose level achievable in Stage 2 *in vivo* mutagenicity tests. [RB8]

Quantitative Structure Activity Relationships (QSAR)

30. The expected mutagenic potential of a chemical can be assessed from its chemical structure, which may provide structural alerts for mutagenicity. The COM has previously agreed that where no genotoxicity data are available, initial assessment of

potential genotoxicity can be based on publicly available QSAR models. A range of QSARs have been developed to predict genotoxicity and COM considered updated information on these models in February 2018. The discussions formed the basis of the COM Statement ‘Use of QSAR models to predict genotoxicity’ (COM, 202x). It was concluded that whilst it remained useful to evaluate data generated from QSAR models, in particular as a negative predictor for screening purposes, no changes to the previously recommended guidance (detailed more fully within the 2011 version of the COM Guidance document; COM, 2011) were warranted.

31. Overall, QSAR approaches for the prediction of genotoxic activity can be a valuable tool to aid in the high throughput screening of compounds, the provision of assessments for chemicals for which no genotoxicity test data are available and also prioritisation for genotoxicity testing. QSAR can also aid in the interpretation of genetic toxicology tests. Expert judgement is needed when reaching conclusions on mutagenic hazard on the basis of QSAR information alone, and such predictions cannot replace the need to undertake the *in vitro* and *in vivo* genotoxicity tests required to derive conclusions on mutagenic hazard [DK9][RB10]. In reaching conclusions, data from well conducted *in vitro* or *in vivo* genotoxicity tests should be attributed a much higher weight of evidence than QSAR predictions, although all information should be assessed on a case-by-case basis.

Screening Tests

32. With regard to this guidance, genotoxicity screening tests refers to high throughput or scaled-down tests which have been designed to be rapid, economical, reproducible, require only small amounts of test chemicals (typically below 50 mg) and have a high concordance with comparator genotoxicity end points in genotoxicity tests; these tests are also often referred to as pre-screening tests. None of the available genotoxicity screening tests have reached the stage of development where they could routinely be used to replace data generated from guideline-compliant *in vitro* genotoxicity testing. COM therefore does not recommend any particular test for screening purposes.

33. A number of *in vitro* systems for use as screening tests have been proposed and are described in full in the previous version of the COM Guidance (COM, 2011). COM is currently preparing a stand-alone document detailing recent advances in screening tests that will sit alongside this Guidance Document [RB11]

Stage 1: In Vitro Genotoxicity Testing

Overview of strategy

34. The COM concluded in 1989, 2000 and 2011 that it was appropriate to concentrate on a relatively small number of assays, using validated, sensitive methods particularly chosen to **avoid misleading negative or positive results** when compared to *in vivo* testing results (Kirkland et al., 2005a, 2007c; Fowler et al., 2012a, b; Matthews et al., 2006; Pfuhler et al., 2011). A detailed justification of the strategy is given in the previous version of the COM Guidance (COM, 2011) and, as such, is not included here.

35. Misleading positive results are considered to be caused by a number of factors, including the use of cell lines of rodent origin (e.g. V79, CHO, C_{HL}) that partially lack normal cell cycle control^[RB12] have limited metabolic capacity (even with the addition of S9) and do not mimic site-specific metabolic capacity (Reus et al., 2013). [The use of p53-competent human cells and careful control of cytotoxicity can help reduce the number of misleading positive results without compromising sensitivity \(Fowler et al., 2012a, b\).](#) The development of 3D tissue models is [also](#) hoped to reduce the number of misleading positive findings and improve the accuracy of predictions due to their improved metabolic capacity and proximity to *in vivo* gene expression and protein functions (Andres et al., 2012; Barcham et al., 2018; [Pfuhler et al. 2020a, b](#)). The current state of the science for 3D model development and validation is discussed in '3D Tissue Models for Genotoxicity Testing' (COM, 2020).

36. As outlined above in paragraph 20 and shown in Figure 2, Stage 1 involves tests for genotoxic activity using *in vitro* methods and comprises a two test core system; namely an *in vitro* bacterial test for gene mutation (Ames test) and an *in vitro* micronucleus test (MNvit), with the objective of assessing genotoxic potential by investigating three different end points (gene mutation, structural chromosomal damage and changes in chromosome number). A detailed justification of the strategy is given in the previous version of the COM Guidance (COM, 2011).

37. **A clear positive result in either of these two core tests is sufficient to define the chemical as an *in vitro* genotoxin, although further *in vitro* and/or *in vivo* testing may be undertaken to understand the relevance of the positive results.** The Committee considers this strategy allows for efficient identification of all genotoxic_end_points and that, by reducing the number of mammalian cell tests and following the most current version of the methodologies, the risk of misleading positive results (i.e. when compared with *in vivo* genotoxicity data) is decreased.

38. Additional investigations of chemicals which give positive or repeated equivocal results in Stage 1 tests can include an assessment of mode(s) of *in vitro* genotoxic

action. There are a number of reasons (discussed in paragraphs 43-45) why positive results in *in vitro* genotoxicity tests might occur by mode(s) of action not relevant to human health hazard assessment. Such mode of action (MoA) evaluation *in vitro* is particularly relevant for those chemicals (e.g. cosmetics) where there is a regulatory constraint which precludes the use of *in vivo* genotoxicity assays in the testing strategy. The COM does not recommend the use of *in vitro* genotoxicity assays that have not been considered in detail in this guidance or for which OECD guidelines either do not exist or have been deleted. This includes assays for sister chromatid exchange, the *in vitro* Unscheduled DNA Synthesis (UDS) assay, the *in vitro* comet assay or tests using fungi or *Drosophila*. A table of genotoxic endpoints detected by each assay cited in Stage 1 of this strategy is given in Annex 1.

39. For chemicals which give equivocal results or repeated small positive effects, when considering biological relevance, it is important to consider evidence of reproducibility in the same assay or in different assays detecting similar effects, and the magnitude of the induced genotoxic effect in relation to historical negative control data, and then consider whether further *in vitro* genotoxicity testing is needed (Hayashi et al., 2011; Kirkland et al., 2007a). Further consideration of SAR data for these chemicals may also give valuable information (Dearfield et al., 2010).

40. If clear negative results are obtained in both core *in vitro* tests undertaken, it can generally be concluded that the chemical has no genotoxic activity. However, there are some occasions when additional *in vitro* and/or *in vivo* genotoxicity testing may be undertaken for chemicals giving a negative response in the two *in vitro* core genotoxicity tests. For example, in situations where tumours are found in rodents, where the *in vitro* metabolic activation systems are not optimal or where there are human-specific metabolites, there may be a need for further genotoxicity assessment. A further testing strategy would have to be designed on a case-by-case basis (Kirkland et al., 2007b; Muller et al., 2003). An IWGT working group has published guidance on this topic (Kasper et al., 2007). An important part of any additional *in vitro* strategy should be consideration of the appropriate exogenous metabolic activation system (including alternative sources of S9 or other metabolic systems including genetically engineered cell lines) (Ku et al., 2007b), or even the testing of specific, relevant metabolites. Further information on *in vivo* genotoxicity testing of such test chemicals is provided in Stage 2 of this strategy.

41. Information from other combinations of genotoxicity tests, which may include one or more non-core tests outlined below in paragraphs 66-71, may also give adequate data on all three end-points on a case-by-case basis. *In vitro* genotoxicity

tests (micronucleus scoring and comet) using human reconstructed skin may provide useful information on *in vitro* mutagenic hazard in circumstances where *in vivo* testing is not permitted, or when extensive dermal exposure is anticipated (e.g. cosmetic ingredients) (Aardema et al., 2013; Chapman et al., 2014; Roy et al., 2016; Reisinger et al., 2018).

42. The full Stage 1 strategy should be performed and the results of studies evaluated before a decision is made on whether to proceed to Stage 2 testing or whether a conclusion on mutagenic hazard can be derived for test chemicals where no *in vivo* genotoxicity testing is permitted. An outline of Stage 0 and Stage 1 (*in vitro* genotoxicity testing) is given in Figure 2 and a description of the assays recommended is provided in the following paragraphs.

Discussion of Stage 1 Tests- General Aspects

43. The conduct of genotoxicity assays has improved over time and the overall sensitivity of *in vitro* testing strategies regarding prediction of rodent carcinogens is very high (Kirkland et al., 2007c; Kirkland et al., 2005a). Proposals have been published for genotoxicity testing advocating a single *in vitro* genotoxicity test (Ku et al., 2007a) or a complex approach involving up to six *in vitro* genotoxicity tests (SCCNFP, 2003). The latter approach has been critically evaluated ((Kirkland et al., 2005a; Kirkland et al., 2005b; Kirkland et al., 2007c; Pfuhler et al., 2011) and although sensitivity (i.e. correct identification of rodent non-carcinogens) was high, specificity (i.e. producing negative results with non-carcinogens) was poor. [RB17]COM considers that neither approach is preferable to the proposed Stage 1 core testing. A comprehensive review of the performance of Stage 1 genotoxicity assays for prediction of rodent carcinogenicity (as assessed by the Carcinogenic Potency Database (CPDB), National Toxicology Program (NTP), and the International Agency for Research on Cancer (IARC)) reported reasonable specificity for the Ames test (74%) but poor specificity for the mammalian cell assays (below 45%) particularly when multiple assays were performed (Elespuru et al., 2009; Kirkland et al., 2005a). Many reasons for low specificity have been proposed, particularly for mammalian cells; for example, the use of high concentrations, [high](#) cytotoxicity, prolonged exposure, overloading defence mechanisms, lack of detoxification capacity. The influence of such confounding effects leading to indirect mechanisms of genotoxicity, has been widely recognised (Kirsch-Volders, 2003; Müller, 2000; Pratt, 2003; Kirkland et al., 2007a)[RB18].

44. Kirkland et al. assessed the sensitivity of a combination of [the](#) Ames test and MNvit test to detect rodent carcinogens and *in vivo* genotoxics (Kirkland et al., 2011). The authors stated that it is difficult to draw precise conclusions from the available sensitivity and specificity data since the databases of chemicals used vary. However, these data do show that mammalian cell genotoxicity tests can have low specificity and that combinations of *in vitro* genotoxicity tests result in high sensitivity for rodent carcinogens and *in vivo* genotoxics. High sensitivity has always been a priority of genotoxicity testing strategies recommended by the COM (DOH, 2000, 2011). COM evaluated the use of *in vitro* genotoxicity tests to predict rodent carcinogens and *in vivo* genotoxics in June 2010 and concluded **that there is no convincing evidence that any [relevant or DNA reactive] rodent carcinogen or *in vivo* genotoxicant would fail to be detected by using an *in vitro* genotoxicity test battery consisting of Ames and MNvit tests**

(<http://webarchive.nationalarchives.gov.uk/20140506144308/http://www.iacom.org.uk/meetings/index.htm>).

45. It is most likely that one of the few occasions where *in vitro* test strategies fail to detect mutagenic activity (i.e. misleading negative results) could be explained by the absence of appropriate metabolic activity *in vitro* (Brambilla and Martelli, 2004) or that the test chemical does not reach the cells. Approaches to resolving potential inadequacies in metabolic activation include structure based metabolism predictions, use of genetically modified target organisms (e.g. CYP2E1 in *Salmonella* YG7108pin3ERb₅) (Emmert et al., 2006), the use of exogenous metabolic activation systems derived from human sources, or recombinant human cytochrome P450 systems as an external activation system (Ku et al., 2007b). [Testing of isolated or synthesised metabolites may also be considered.](#)

46. There are a number of MoAs by which a chemical may demonstrate an *in vitro* genotoxic effect that is either not relevant for humans (e.g. a rat specific metabolite) or has a threshold. The COM has reviewed the evidence for a number of threshold MoAs and published a general guidance statement in 2010 (<https://www.gov.uk/government/publications/assessment-of-thresholds-for-in-vitro-mutagens>)

47. Threshold MoAs can generally be attributable to non-DNA interactions or an overload of normal cellular physiology. In such cases a No Observed Effect Concentration (NOEC) can be determined and may be useful in evaluating risk.

Investigations of a threshold-based MoA need to be designed on a case-by-case basis and can be complex to interpret (Kirkland et al., 2007a).

48. There has been considerable debate regarding the highest concentration that should be used routinely in mammalian cell assays. The ICH has stated the maximum concentration tested for human pharmaceuticals should be 1 mM (or 5000 µg/mL) in mammalian cell genotoxicity assays (ICH, 2012) which would have the effect of reducing the number of misleading positive results by avoiding the excessive concentrations where the cellular defence mechanisms might be overwhelmed (ICH, 2012). However, a reduction to 1 mM is not consistent with the OECD recommendation for a top concentration of 10 mM (or 2000 µg/mL) in mammalian cell genotoxicity assays (OECD, 2016a,c,d,e). Morita et al. (2014) showed that the reduction in the top concentration from 5000 to 2000 µg/mL for mammalian cell tests had no impact on sensitivity or specificity of *in vitro* chromosomal aberration tests. Another analysis of published data for the top concentration in mammalian cell genotoxicity tests identified a small number of carcinogens that (according to the publications) would not be detected in any part of a three test *in vitro* genotoxicity test battery (consisting of the Ames, mouse lymphoma and *in vitro* chromosomal aberration (CA) tests) if the testing concentration limit for mammalian cell assays were reduced from 10 mM to 1 mM (Parry et al., 2010). A further investigation of these carcinogens found that some positive results at concentrations above 1 mM were not reproducible (i.e. they were not genotoxic in mammalian cells under current OECD guideline protocols) and others were positive at concentrations below 1 mM, particularly when continuous treatments in the absence of S-9 (not included in the original publications) were conducted. A new upper limit for mammalian cells tests of 1 mM or 500 µg/ml (whichever is higher) has been proposed as sufficient to detect all genotoxic carcinogens that are negative in the Ames test (Kirkland and Fowler, 2010). Several international organisations have updated their guidance regarding upper limit selection (e.g. ICH, 2012, OECD, 2020a; Galloway et al., 2011) although currently no international consensus has been reached. Precipitation of the chemical in the medium can also be used to define a maximal concentration or upper limit for testing. On balance, COM agreed that the maximum concentrations identified in ICH S2(R1) should be adopted. [DK19][RB20]

49. There has also been considerable investigation of the role of excessive cytotoxicity in mammalian cells and choice of cell type as possible causes of misleading positive results (Blakey et al., 2008; Fellows et al., 2008b; Pfuhler, 2009; Pfuhler et al., 2011). The method used to assess cytotoxicity may affect the selection of the highest concentration tested and potentially the results obtained using

mammalian cell genotoxicity assays (Fowler et al., 2012b; Kirkland et al., 2007c; Kirkland, 2012a) and recommendations have been made to use cytotoxicity measures based on cell proliferation (Galloway, 2000). However, it is important to note that although excessive cytotoxicity may lead to misleading positive results, it may also result in misleading negative results when pronounced cell cycle delay occurs. A similar conclusion was reached at an international symposium on regulatory aspects of genotoxicity testing (Blakey et al., 2008).

50. Most cell lines used for genotoxicity testing lack appropriate metabolism leading to reliance on exogenous metabolic activation systems. These cell lines may often have impaired p53 function and altered DNA repair capacity (Kirkland et al., 2007c). There is some evidence that human lymphocytes are less susceptible to misleading positives than the rodent cell lines currently used (e.g. Chinese Hamster Ovary (CHO), V79, Chinese hamster lung (CHL)). The use of human cell lines HepG2, TK6 and MCL5 cells and the reconstructed human skin models and HepaRG [are being] [DK21][RB22][RB23] evaluated (Fowler et al., 2012a; Kirkland et al., 2007c; Le Hegarat, 2010). A brief summary of 3D models currently used for genotoxicity testing and those under development and/or validation has been prepared by COM (COM, 2020^x).

51. The COM agrees that it is not necessary to [undertake independent confirmatory *in vitro* tests][RB24] when clear negative or positive results have been obtained provided the following criteria are satisfied:

- there is no doubt as to the quality of the study design and the conduct of the test;
- the spacing and range of test chemical concentrations rule out missing a positive response; and
- sufficient treatment conditions and sampling times have been used.

52. It is recognised that it can be difficult to provide convincing evidence for absence of genotoxic effects. The investigator should consider the power of the study design and the past performance of the test system when formulating a protocol in order to optimise the chances of obtaining an unequivocal result from a single experiment and to ensure that any potential genotoxic effect is not missed.

53. [There is a need to][undertake further *in vitro* genotoxicity testing][DK25][RB26][when an equivocal result is obtained][RB27](i.e. neither clearly negative nor clearly positive by appropriate biological or statistical criteria). Such additional genotoxicity tests need to be planned on a case-by-case basis and need not necessarily be undertaken in an

identical fashion to the initial experiment(s). Indeed, it may be preferable to alter certain aspects of the study (e.g. concentration levels investigated, treatment and sampling times, concentration of metabolic activation mix) to obtain supplementary data. It may also be appropriate to use a different genotoxicity test system, e.g. a chromosomal aberration (CA) test, if there is equivocal evidence of clastogenicity from an *in vitro* micronucleus test, or an *in vitro* cell mutation assay (e.g. TK or HPRT mutation assays) if there is equivocal evidence of gene mutations from an Ames test.

54. The use of historical negative control data to aid in the interpretation of genotoxicity test results has been considered particularly in relation to equivocal and small magnitude genotoxic effects (Hayashi et al., 2011). Advice has been published on approaches to collecting historical control data. Ideally data should be reported in terms of means and confidence intervals for the distribution of baseline genotoxic effects rather than observed ranges where outliers can have a disproportionate effect. The dataset should be updated regularly and should be as large as possible. In addition, it is important that negative historical control data should have been generated using a fixed testing protocol [RB28] unless it can be demonstrated that changes in protocol do not impact on the range of values reported in studies (Hayashi et al., 2011). In their most recent guidance OECD places an increased emphasis on the use of historical concurrent negative control data in the assessment of genotoxicity test results, including recommendations on how to build an historical control database (OECD, 2020a).

55. If a chemical is considered on the basis of Stage 1 genotoxicity test results to have *in vitro* genotoxic potential but has not been tested *in vivo*, the COM considers it prudent to assume that the chemical may have *in vivo* genotoxic potential.

Discussion of Stage 1 Strategy: Specific Core Tests

In Vitro Bacterial Tests for Gene Mutations

56. The most widely used *in vitro* mutagenicity test is the bacterial reverse mutation assay for gene mutations developed by Ames and his colleagues using *Salmonella typhimurium* (Gatehouse et al., 1994) which forms the basis of OECD TG471 (Bacterial Reverse Mutation Test). The very extensive database available for this assay justifies its inclusion in any initial genotoxicity testing for mutagenic hazard. Several strains of bacteria capable of detecting both base-pair and frame-shift mutations must be included, the validated strains being TA1535, TA1537 (or TA97 or TA97a), TA98 and TA100. [DK29][RB30] These strains detect effects at G-C-rich sites. To detect certain oxidising mutagens or hydrazines, that produce effects at A-T-rich sites, an additional

strain such as TA102 or a repair-deficient *Escherichia coli* strain (WP2uvrA or WP2uvrA (pKM101)) should be included. To detect cross-linking agents, it may be preferable to include TA102 or to add a repair proficient *Escherichia coli* strain (WP2 or WP2 (pKM101)). Testing should be carried out both in the presence and absence of an appropriate exogenous metabolic activation system such as induced rat liver S-9. Both plate-incorporation and pre-incubation methods are widely used, and either is acceptable in all test guidelines. The sensitivity and selectivity of the bacterial strains specified in OECD TG471 have been assessed (Williams et al., 2019) and the current criteria for a valid Ames test and interpretation of test results evaluated (Levy et al., 2019).

57. Developments to the Ames test have been suggested to automate and minimise the amount of test chemical required; for example the Spiral *Salmonella* mutagenicity assay (Claxton et al., 2001)^[RB31], Ames IITM test (Fluckigetr-Isler et al., 2004) and Ames MPF (Fluckigetr-Isler and Kamber, 2012; Spiliotopoulos and Koelbert, 2020). The Committee considers that these methods have not currently been developed to a point where they can be routinely used for regulatory submissions.^{[DK32][RB33]}

In Vitro Mammalian Cell Micronucleus Assay (MNvit) for Clastogenicity and Aneuploidy

58. The COM recommends that equivalent information on clastogenicity could be obtained from the MNvit compared with CA testing in mammalian cells (metaphase analysis) but that aneuploidy could be more easily detected by MNvit. There have been extensive and authoritative investigations of the utility of the MNvit which have concluded that the MNvit is reliable and can be used as an alternative to the *in vitro* CA for the assessment of clastogenicity and has the benefit of more easily detecting aneuploidy (Corvi et al., 2008). The MNvit is available as OECD TG 487 (In Vitro Mammalian Cell Micronucleus Test) (OECD, 2016a). ~~Although some *in vitro* genotoxicity testing strategies recommend that the micronucleus assay and metaphase analysis can be considered as equivalent in the detection of clastogens the COM recommends the MNvit assay as the first choice test for clastogenicity and aneuploidy detection.~~^{[DK34][RB35]}

59. The MNvit can be carried out in the absence or presence of cytochalasin B, which is used to block cytoplasmic division^{[DK36][RB37]} and generate binucleate cells (cytokinesis block methodology (CBMN)). The advantage of using cytochalasin B is that it allows clear identification that treated and control cells have divided *in vitro* during or after treatment and provides a simple assessment of cell proliferation.

Moreover, a defined population of binucleate cells is available for scoring. In general, the use of cytochalasin B has no impact on the sensitivity of the test results (Garriott et al., 2002; Lorge et al., 2006; Oliver et al., 2006; Wakata et al., 2006), however this is not the case for nanoparticles (COM, 202x). In the absence of cytochalasin B, where all cells will be mononucleate, it is essential to have evidence that cells have divided.

60. MNvit protocol development and assay performance have been previously described (COM, 2011; Fowler et al., 2012a, b). A flow cytometric approach to the micronucleus assay has also been developed (Bryce et al., 2013). MNvit assay can be performed using most mammalian cell lines used in genotoxicity testing however there is evidence that rodent cell lines with compromised p53 activity such as V79, CHO and CHL cells can give more misleading positive results than cell lines proficient for p53 activity such as TK6 and human lymphocytes (Fowler et al., 2012a). Overall, the COM's preference is for human lymphocytes which have a number of advantages over cell lines (e.g. normal diploid primary human cells with some protection against oxidative damage when whole blood cultures are used). If cell lines are used, it is important that the cells have defined provenance (Lorge et al., 2016) and that the impact of potential genetic drift of the cells cultured is understood (Kirkland et al., 2007c). [DK38][RB39] One particular area of protocol development that has been under considerable investigation is the most appropriate method(s) for estimating cytotoxicity as it has been suggested that using relative cell counts (RCC) may underestimate cytotoxicity and lead to potentially misleading positive results (Fowler et al., 2012b). [DK40][RB41] In the absence of cytokinesis block, the relative increase in cell count (RICC) or relative population doubling (RPD) are comparable with replication index (RI) used with the cytokinesis block assay and are the most appropriate methods of cytotoxicity estimation. Consensus recommendations embedded in the OECD guideline 487 indicate that the target range for cytotoxicity in the MNvit is $55 \pm 5\%$.

61. The MNvit assay in combination with the CB methodology and with pancentromeric or chromosome specific centromeric probes fluorescence *in situ* hybridisation (FISH) provides a sensitive assessment of cell proliferation and allows discrimination between chromosome breaks, chromosome loss (using pancentromeric or anti-kinetochore antibodies) and chromosome non-disjunction and polyploidy (using chromosome-specific centromere probes) (Kirsch-Volders et al., 2002). It is therefore a useful model for assessing mode of action (Parry, 2006).

62. Binucleate cells obtained with the CBMN will usually be needed for determination of non-disjunction of chromosomes between daughter nuclei. Fenech has proposed that the CBMN assay can be further modified to provide comprehensive

information on nucleoplasmic bridges (NPBs). This may provide information on chromosome rearrangements or telomere end fusions, and nuclear buds (NBUDs) which may provide information on gene amplification (Fenech, 2006, 2007). Fenech proposed that the comprehensive CBMN assay should be considered as a 'cytome' method for measuring chromosomal instability and altered cellular viability (Fenech, 2006). The 'cytome' method is complex and requires large amounts of blood and considerable technical skill. It is currently not suitable for routine testing of chemicals for genotoxicity but may provide useful information on MoA.

63. The flow-cytometry-based micronucleus assay (FCMMN) was developed to increase reproducibility and decrease turnaround time for the micronucleus test (Laingam et al., 2008; Avlasevich et al., 2011). However, the modified assay did not overcome the potential issue of misleading positive results. A number of approaches were undertaken to overcome this and have been previously described (COM, 2011). A separate approach to automation of the CBMN assay involves automated image analysis (Decordier et al., 2009; Avlasevich et al., 2011; Seager et al, 2014, Chapman et al, 2014, Lyulko et al 2014; Thougard et al., 2014; Buick et al., 2020). This does provide some advantages over the FCMMN assay as the cells are not destroyed in the analysis and it can be applied to the cytokinesis blocked micronucleus assay. Thus, micronuclei can be scored in binucleated cells, cells containing multiple micronuclei can be easily identified and scored as a single event, and the image galleries and slides can be stored, allowing the experiment to be re-visited at a later date.

64. An interlaboratory evaluation of the MultiFlowVR DNA Damage kit— p53, [gamma](#) H2AX, Phospho-Histone H3 [and polyploidy](#) [\[DK42\]](#) [\[RB43\]](#) has been described by Bryce et al. (2017). This is a multiplexed *in vitro* genotoxicity assay based on flow cytometric analysis in which detergent-liberated nuclei are simultaneously stained with propidium iodide and labelled with fluorescent antibodies against p53, gH2AX, and phospho-histone H3. [Polyploidy can be quantified as the proportion of 8n-positive events relative to the number of total events with 2n and greater DNA content.](#)

65. From seven laboratories assessing chemicals representing clastogens, aneugens and non-genotoxicants, with analysis based on global evaluation factors and using a multinomial logistic regression, assay sensitivity, specificity and concordance in relation to a priori MoA grouping were 92%. The authors suggest that the two distinct analysis strategies utilised can be used to rapidly and reliably predict a genotoxic MoA for new chemicals.

Discussion Stage 1: Non-Core Tests

In Vitro Chromosomal Aberration Assay in Mammalian Cells (Metaphase Analysis) for Clastogenicity and Aneuploidy

66. The *in vitro* CA assay in mammalian cells has been widely used in genotoxicity testing for many decades and provides information on chromatid and chromosome breaks, deletions and re-arrangements that are indicative of damage associated with adverse health outcomes. Only limited information can be obtained on potential aneugenicity by recording the incidence of polyploidy and/or modification of mitotic index (Aardema et al., 1998). The COM notes that polyploidy may not be a reliable indicator for aneugenicity and may result from a number of different genetic changes (Galloway, 2000; Mitchell et al., 1995). It is possible to adapt the chromosome aberration assay to include the use of chromosome specific centromeric probes with fluorescence *in situ* hybridisation (FISH) to assess the potential for aneuploidy (Maierhofer et al., 2002). An IWGT report (Galloway, 2000) concluded that the preferred measure of cytotoxicity in the CA test should be one based on cell proliferation (e.g. relative population doubling or relative increase in cell counts) compared to negative control cultures rather than simple cell counts. On balance it is considered preferable to use the *in vitro* micronucleus test for the initial assessment of clastogenic and aneugenic potential. The latest revision of the OECD test guideline (OECD, 2016c) utilises a maximum test concentration corresponding to 10 mM (or 2 mg/mL) which is in-line with the revised MNvit assay (OECD, 2016a).

In Vitro Mouse Lymphoma Assay for Gene Mutation and Clastogenicity

67. The COM reaffirms the view stated in the 1989, 2000 and 2011 guidance, that the most appropriate *in vitro* mammalian cell gene mutation test is the mouse lymphoma assay. Protocol development and test data interpretation strategies were discussed previously (COM, 2011).

68. A re-evaluation of published studies, many of which were undertaken by the US NTP, showed that a large number of these were uninterpretable or the outcomes equivocal (Schisler et al., 2018). [This assay is now described in a separate OECD TG \(Test 490: In Vitro Mammalian Cell Gene Mutation Test Using the Thymidine Kinase Gene\) which](#) was published in 2016 (OECD, 2016d). Some authors have reported that the mouse lymphoma assay can detect, in addition to gene mutations and clastogenicity, information on recombination, deletion and aneuploidy (Ogawa et al., 2009; Sofuni, 1996; Wang et al., 2009). However, this has been contested from results showing that none of 7 reference aneugens were reliably detected at acceptable levels of cytotoxicity (Fellows et al., 2011b). It is possible that aneuploidy in these cells could

be a secondary effect of chromosomal rearrangement. However, the COM considers that this assay does not reliably detect aneuploids.

In Vitro HPRT assays for Gene Mutation

69. An *in vitro* cell mutation assay which uses forward mutation in the hypoxanthine guanine phosphoribosyl transferase (HPRT) gene to assess mutations has been developed in several cell lines, principally CHO cells and is described in the revised OECD 476 guideline (OECD, 2016e). TG476 recommends that the minimum number of cells required for the assay should allow for at least 10 spontaneous mutants being present in all phases of the test. The COM have previously considered the power of this assay and it was concluded that 10^7 surviving cells are required for a valid test, [DK44][RB45](<http://webarchive.nationalarchives.gov.uk/20140506144831/http://www.iacom.org.uk/meetings/02.10.2003.htm>), providing sufficient numbers of cells to maintain between 10 and 100 spontaneous mutations.

70. As discussed in para 43, a number of research groups have developed genotoxicity assays based on MN measurement using commercial sources of human reconstructed skin (such as Episkin[®] and EpiDerm[™]) (Chapman et al., 2014; Curren et al., 2006; Flamand et al., 2006; Hu et al., 2009; Mun et al., 2009; Roy et al., 2016; Pfuhler 2020a,b) or a co-culture technique involving reconstructed skin and mouse lymphoma L5178Y cells (Flamand et al., 2006). Measurement of DNA damage using the comet assay in reconstructed skin has also been reported (Pfuhler et al., 2011; Reisinger et al., 2018; Pfuhler et al., 2020b) and is considered to be sufficiently validated to start the OECD Test Guideline development process (Pfuhler et al., 2020b). The primary purpose in developing genotoxicity tests using reconstructed skin has been to supplement genotoxicity data-packages for cosmetic chemicals where no *in vivo* genotoxicity tests are permitted.

In Vitro Alkaline Comet Assay for DNA Damage

70.71. The *in vitro* alkaline comet assay for DNA damage has been proposed as an alternative to clastogenicity assessment in mammalian cells since cell proliferation is not needed, therefore any cell type can be used (Hartmann et al., 2001; Witt et al., 2007). The alkaline comet assay detects a wide range of genetic damage including single and double strand breaks, repair induced breaks, alkali labile lesions and abasic sites. There is evidence that the *in vitro* comet assay can be modified to detect DNA cross-linking agents (Spanswick et al., 2010). The comet-FISH assay has been developed to provide information on site specific DNA strand breaks (Glei et al., 2009; Rapp et al., 2000; Santos et al., 1997). There is evidence that the *in vivo* comet assay

can detect chemicals that induce gene mutations *in vitro* [and in vivo](#) (Dertinger et al., 2010; Kirkland and Speit, 2008; [Kirkland et al. 2019a, b](#)). Extrapolation from this suggests that the *in vitro* comet assay can also detect chemicals that induce gene mutations and this capability has been demonstrated (Dertinger et al., 2010). However, it is not recommended as a routine replacement for gene mutation tests *in vitro*. Thus, the comet assay measures DNA damage irrespective of genotoxic end-point, with the exception of aneuploidy. A positive comet assay result may be due to repairable DNA damage or lesions which lead to cell death and not necessarily [lead to](#) mutations or MN. Negative results from an Ames test and MNvit would reduce the level of concern associated with positive results from an *in vitro* comet assay. Thus, the *in vitro* comet assay can serve as a useful adjunct to the recommended core-tests, especially in instances where *in vivo* testing is not permitted such as in cosmetics testing. Pfuhler et al. (2020b) has reviewed the status of the development of the 3D organ-based models for genotoxicity testing. The authors concluded that the 3D skin comet assay was sufficiently validated to start the process of [OECD Test Guideline development](#). [\[RB46\]](#)

Summary Stage 1 (*In Vitro* Genotoxicity Testing)

[71-72](#). The COM recommendations for Stage 1 testing remain the same as in the 2011 guidelines, namely that the three key endpoints of gene mutation, clastogenicity and aneuploidy can be detected by using two core *in vitro* tests. Tests should be undertaken according to the best international guidance available to avoid misleading positive or negative results. Data should be interpreted using appropriate statistical analysis and use of historical negative control data.

[72-73](#). The COM confirms the need to understand MoA in order to derive conclusions regarding the biological importance of results. Data on MoA are important in elucidating whether genotoxicity tests give misleading negative or positive results, and also to aid decisions with regard to devising a strategy for Stage 2 *in vivo* genotoxicity [testing](#). [\[RB47\]](#) There is a particular need to understand MoA for chemicals which cannot be subjected to *in vivo* genotoxicity tests (e.g. cosmetics). In this particular instance, some useful additional information on genotoxicity may be provided by undertaking further testing, for example using *in vitro* mammalian cell gene mutation assays or *in vitro* MN and comet tests using reconstructed human skin.

[73-74](#). The recommended two core genotoxicity tests in Stage 1 are the Ames test and MNvit. These recommended assays, when combined, provide sufficient information for the genotoxicity assessment of most chemicals and provide high

sensitivity for the identification of rodent carcinogens and *in vivo* genotoxicants, and reduce the risk of misleading positive results when compared with a battery containing more than one mammalian cell test.

~~74-75.~~ Results from non-core tests described in this document may provide useful additional information on *in vitro* mutagenic hazards on a case-by-case basis. In most instances misleading negative *in vitro* results are due to inadequate exogenous metabolic activation (Ku et al., 2007b).

~~75-76.~~ Some regulatory authorities may require an *in vivo* genotoxicity test where high, or moderate and prolonged, levels of exposure are expected (e.g. most human medicines) in order to provide additional reassurance even when Stage 1 tests have given negative results. If a chemical is considered on the basis of Stage 1 test results to have *in vitro* mutagenic potential but has not been tested *in vivo*, the COM considers it prudent to assume that the chemical may have *in vivo* mutagenic potential.

Stage 2: *In Vivo* Genotoxicity Tests

Overview of Strategy

Stage 2 of the testing strategy involves an assessment of genotoxic activity *in vivo* in somatic tissues and in germ cells (when there is a need for the assessment of heritable effects and/or information on hazard classification of mutagens) (see Figure 3). The *in vivo* genotoxicity testing strategy has to be designed on a case-by-case basis and can be used to address aspects of *in vivo* mutagenicity, for example;

1. Investigation of key end point(s) identified in Stage 1,
2. Investigation of genotoxicity in tumour target tissue(s),
3. Investigation of potential for germ cell genotoxicity,
4. Investigation of *in vivo* genotoxic potential for chemicals which were negative in Stage 1 but where there is high or moderate and prolonged exposure.
5. Investigation of genotoxicity in site of contact tissues.

~~76-77.~~ It is thus possible for there to be one or more separate Stage 2 strategies designed to assess the above objectives for a particular test chemical. A revised *in vivo* Stage 2 strategy was presented in the previous COM guidance document (COM, 2011) based on the selection of tests to provide information on one or more specific aspects such as species and/or tissue genotoxicity combined with investigation of particular genotoxic end points and modes of genotoxic action. This approach does

not necessarily lead to the selection of the rodent BMMN test as the first assay. Furthermore, the rat liver UDS assay is no longer recommended as a second assay (EFSA, 2017 - discussed in para 104). A table of *in vivo* genotoxicity tests and end-points is provided in Annex 1.

~~77-78.~~ Other factors that should be considered when determining an *in vivo* genotoxicity testing strategy include whether the testing strategy can be integrated into other regulatory toxicity tests (such as subacute or subchronic toxicity studies). Consideration needs to be given to the nature of the chemical (including physico-chemical properties), the results obtained from *in vitro* genotoxicity tests and the available information on the toxicokinetic and metabolic profile of the chemical (for example when selecting most appropriate species, tissue and end point). The routes of exposure in animal studies should be appropriate to ensure that the chemical reaches the target tissue. Routes unlikely to give rise to significant absorption in the test animal should therefore be avoided. Unless systemic exposure can be confirmed from other toxicological studies, or evident toxicity in the target organ is seen, [or the intravenous route is used](#), confirmatory toxicokinetic studies to measure blood or tissue exposure as appropriate should be undertaken to accompany all *in vivo* genotoxicity studies to assess the adequacy of any negative results obtained (Hardy et al., 2017).

~~78-79.~~ The design of *in vivo* genotoxicity tests should incorporate appropriate approaches to reduce the number of animals used in tests, such as the integration of genotoxicity endpoints into repeat-dose studies. Options for reduction in animal usage include:

- use of one sex only (if supported by metabolism data or other data indicating equivalence),
- reduced numbers of sampling times for micronucleus and CA assays when repeat dosing is performed,
- combining micronucleus and comet assays into a single acute test employing repeated administrations of test chemical; integration of micronucleus and comet end points into repeat-dose toxicity (including transgenic mutation) studies, although it should be noted that the comet assay is difficult to integrate without using satellite groups (Bowen et al., 2010; Bowen and Beevers, 2011; Pfuhler et al., 2009; Vasquez, 2010).

~~79-80.~~ It should also be possible to omit the concurrent positive control administrations in micronucleus, CA and transgenic rodent mutation assays (but not for the comet

assay) where the test facility has appropriate historical positive control data (Pfuhler et al., 2009) as long as positive control slides or tissues from positive control treated rodents “banked” from previous treatments and coded in with the experimental samples, are included to demonstrate technical proficiency.

80-81. The toxic properties of test chemicals (such as acute toxicity, subchronic toxicity (including target organ effects), irritancy/corrosivity in contact with skin or mucous membranes), toxicokinetic and metabolism data will influence the choice of route of administration and the highest dose level achievable in *in vivo* mutagenicity tests. Dose selection for *in vivo* genotoxicity testing [DK48][RB49] requires estimation of the maximum tolerated dose, consideration of tissue-specific effects and in some instances (as discussed in paragraph 78), appropriate toxicokinetic data or toxicity data in the target tissue from other studies, to support tissue exposure to the chemicals and/or metabolites (Hardy et al., 2017).

81-82. The approach outlined for Stage 2 in Figure 3 takes account of evidence to suggest that *in vivo* comet and rodent transgenic mutation assays have better sensitivity and specificity for the identification of rodent carcinogens compared with the rat liver UDS test, particularly for carcinogens that are negative in the *in vivo* micronucleus test (Kirkland and Speit, 2008). The initial *in vivo* genotoxicity testing strategy should therefore involve selection of one or more of the core Stage 2 tests in rodents; namely, micronucleus tests (accompanied by specific assays [DK50][RB51] for aneuploidy if necessary), the transgenic gene mutation tests, or comet DNA damage assays in rodents. It is acceptable to undertake one *in vivo* genotoxicity test to investigate a specific end point identified from Stage 1 *in vitro* genotoxicity tests. In some instances, there may be a need to investigate more than one end point before reaching a full conclusion on *in vivo* genotoxic potential.

82-83. Stage 2 *in vivo* genotoxicity tests should be undertaken for test chemicals that are positive in any of the *in vitro* Stage 1 genotoxicity tests where there is a need to ascertain whether genotoxic activity can be expressed *in vivo*. There are many reasons why activity shown *in vitro* may not be observed *in vivo* (for example, lack of absorption, inability of the active metabolite to reach DNA, rapid detoxication and elimination). Data from *in vivo* genotoxicity tests are, therefore, essential before any definite conclusions can be drawn regarding the potential mutagenic or genotoxic hazard to humans from test chemicals which have given positive results in one or more *in vitro* genotoxicity tests. However, conclusions on mutagenic or genotoxic hazard and MoA may have to be derived from *in vitro* genotoxicity data for test chemicals when no *in vivo* genotoxicity testing is permitted.

83-84. In addition, an *in vivo* genotoxicity test may give positive results for chemicals which only act *in vivo*; experience though, has shown that such chemicals are rare (Tweats, 2007a,b). Such agents include some kinase inhibitors, glucocorticoid receptor antagonists (Hayes et al., 2013) and long-acting beta-2-agonists (Ponten et al., 2013). In some instances positive results might be obtained from *in vitro* genotoxicity tests that are adapted to evaluate specific characteristics of the test chemical; for example, by the use of modified or non-standard exogenous metabolising fractions (Muller et al., 2003).

84-85. Positive results in any Stage 2 genotoxicity test should be assessed for an indication of a MoA^[RB52] and for evidence which may suggest a threshold of effect or irrelevant positive responses. The COM has previously discussed the relevance of high-dose only positives and recognises that these results may be secondary to non-genotoxic effects rather than being a genotoxic effect of the compound (<http://webarchive.nationalarchives.gov.uk/20140506144902/http://www.iacom.org.uk/statements/COM03S5.htm>).

85-86. Examples of MoAs that may lead to irrelevant positive responses in micronucleus tests, include hypothermia or hyperthermia in rodents and compound induced increases in cell division of bone marrow erythroblasts (Blakey et al., 2008; Shuey et al., 2007; Tweats et al., 2007a). If the conclusion is reached that a MoA occurs^{[DK53][RB54]}, then the chemical should be considered as an *in vivo* mutagen. MoA data will be important in considering whether a threshold or non-threshold approach to risk assessment can be used. The COM has published guidance on possible threshold modes of genotoxicity which can include; i) involvement of non-DNA targets, (e.g. aneugen inhibition of microtubules), ii) the contribution of protective mechanisms (e.g. repair of DNA adducts formed from many low molecular weight alkylating agents) and, iii) overload of detoxication pathways (e.g. paracetamol) (https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/315698/assessment_of_threshold_for_in_vivo_mutagens.pdf).

86-87. Supplementary *in vivo* tests should be undertaken^{[DK55][RB56]} if the results of the core *in vivo* genotoxicity test(s) (Figure 3) give equivocal results or if there is a need to investigate specific mutagenic endpoints, tumour target organs, or the potential for heritable effects. This may involve repeating all or aspects of the initial Stage 2 testing strategy, or performing supplementary investigations (e.g. mode of action investigations, such as DNA adducts or more specific germ cell testing) to investigate aspects of the genotoxicity of the test chemical which have not been resolved. There is a need to select the most appropriate test(s) on a case-by-case basis. All relevant

factors, such as results from previous tests, and available information on toxicokinetics, toxicological effects and metabolism of the chemical, should be considered.

87-88. The development of testing strategies for germ cell mutagens is a rapidly evolving field. A summary of test methodologies that are currently under development and/or validation are outlined in the COM document 'Test Strategies for Germ Cell Mutagens' (COM, 202x).

88-89. One aspect of the approach to testing outlined in Figure 3 is that hazard characterisation of germ cell genotoxicity can be included in the initial *in vivo* genotoxicity testing strategy if considered necessary. This is because there are multi tissue *in vivo* genotoxicity assays (e.g. transgenic rodent mutation assays and comet assay, though it should be noted that the standard comet assay has not been validated using mature sperm) which can also be used if a need to evaluate germ cell genotoxicity has been established (COM, 202x). Additionally, germ cell mutation assays might be valuable on a case-by-case basis to provide information on heritable mutagenic effects, but these would form part of a supplementary *in vivo* genotoxicity testing strategy, if considered appropriate.

89-90. The COM reaffirms that a chemical considered a positive *in vivo* somatic cell mutagen should also be considered as a possible germ cell mutagen unless data can be provided to the contrary. The position held previously, that most if not all germ cell mutagens are also genotoxic in somatic cells, still holds true. It has been noted that some rare examples (e.g. sodium orthovanadate, (Attia et al., 2005) where the mouse bone marrow micronucleus assay does not predict germ cell genotoxicity have been reported. However, the data on such compounds are conflicting and it is not known, for example, whether somatic mutations or DNA strand breaks would have been identified if other test systems (e.g. transgenic assays and the comet assay) had been used and other tissues sampled (Attia et al., 2005; Ciranni et al., 1995; Witt et al., 2003).

90-91. It is plausible that other targets during the process of meiotic cell division may be unique to germ cells but not necessarily identical in both sexes (Pacchierotti et al., 2007). The COM evaluated advances in germ cell mutagenicity testing and some theories and hypotheses regarding human germ cell mutagenesis. It was concluded that further validation work was needed before newly developed germ cell assays, such as the sperm comet assay, could be incorporated into general genotoxicity testing. There are a number of methodological difficulties involved in the analysis of germ cells compared to somatic cells (e.g. germ cell DNA extraction) and the

importance of good study design was highlighted. The COM concluded that it is not known whether unique germ cell mutagens exist (i.e. chemicals that are germ cell mutagens but not somatic cell mutagens), but that this is partially because of the underutilisation of the currently accepted tests for assessing germ cell mutagenicity and a lack of investigations examining this.

Discussion of Stage 2 Initial Testing Strategy - General Aspects^[RB57]

[91-92](#). There are many publications debating *in vivo* genotoxicity testing strategies. For example, the GUM (German speaking section of the European Environmental Mutagen Society) recommended a single study using a combined analysis for MN and comet induction in selected tissues (Pfuhler et al., 2007), while the World Health Organization/International Programme on Chemical Safety (WHO/IPCS) recommended cytogenetics (bone marrow) or gene mutation or alternative tests as defined by genotoxic end-point, chemical class and reactivity (with consideration of factors such as bioavailability and metabolism) (Eastmond et al., 2009). The *in vivo* genotoxicity testing strategy recommended by the COM acknowledges there can be a variety of reasons for undertaking *in vivo* genotoxicity tests and it is important to identify clearly the objective of the study and the critical aspects of *in vivo* genotoxicity to be addressed (as set out in the Overview of Stage 2 strategy) in order to develop a strategy accordingly, rather than simply specify preferred first and second tests. There are less data on the performance of *in vivo* genotoxicity assays for prediction of rodent carcinogenicity compared [with](#) data on the performance of *in vitro* genotoxicity tests. Transgenic rodent mutation assays and the *in vivo* micronucleus assay have been shown to exhibit complementarity regarding prediction of rodent carcinogenicity, consistent with the assessment of different mutagenic end-points by these two assays (Morita et al., 2016). The IWGT has reported that an evaluation of 91 chemicals showed that TGR and *in vivo* comet assays have a similar ability to detect *in vivo* genotoxicity when tested with bacterial mutagens and Ames-positive carcinogens (Kirkland et al., 2019^b). Thus, genotoxic end-point and MoA analysis of *in vitro* mutagenic activity is of considerable importance in helping to develop an initial *in vivo* genotoxicity testing strategy. The COM recommends that the initial *in vivo* genotoxicity testing strategy should be based on one or more tests selected from a relatively limited number of *in vivo* genotoxicity tests that have been specifically designed to provide the optimum amount of information on *in vivo* mutagenic potential of the test chemical.

Discussion of Stage 2 - Recommended *In Vivo* Genotoxicity Tests

92-93. Three recommended *in vivo* genotoxicity tests are outlined below and in Figure 2. Information from one or more of these recommended core tests should provide sufficient *in vivo* genotoxicity data for most chemicals.

Rodent Bone Marrow and Peripheral Blood MN Assay for Clastogenicity and Aneuploidy
OR Rodent Bone Marrow CA Assay for Clastogenicity

93-94. The *in vivo* bone marrow or blood micronucleus (MN_{viv}) assay is still the most widely used *in vivo* genotoxicity test (OECD TG 474: Mammalian Erythrocyte Micronucleus Test) (OECD, 2014). Most of the available *in vivo* data on the mutagenicity of chemicals have been obtained from studies using the MN test in bone marrow of mice. The bone marrow is readily accessible to chemicals that are present in the blood and a wide range of structurally diverse clastogens and aneugens has been detected using these methods. The use of peripheral blood is an alternative approach for both mice and rats (when the youngest fraction of reticulocytes are sampled) which provides equivalent data to the bone marrow assay and is technically less demanding. High throughput approaches to the peripheral blood MN_{viv} utilising flow cytometry have been published (De Boeck et al., 2005; Torous et al., 2000) however these remain poorly validated [DPL58][DK59][RB60]. The MN_{viv} assay detects clastogenicity by measuring MN formed from acentric chromosome fragments in young (polychromatic) erythrocytes in the bone marrow or in reticulocytes of peripheral blood. It may also be used to identify the induction of chromosome loss. MN containing whole chromosomes (as opposed to fragments) can be identified with molecular kinetochore [RB61] or centromeric labelling techniques. It should be noted that only aneuploidy produced by chromosome loss can be measured in the MN_{viv} assay. The MN_{viv} can be used in the initial *in vivo* genotoxicity strategy for generic testing for *in vivo* genotoxic potential and for assessment of clastogenicity and aneuploidy. Clastogenicity may be measured by metaphase analysis of CA in bone marrow of rodents as an alternative approach to the use of the micronucleus assay.

94-95. Proposals have been published to incorporate micronucleus assays into routine rodent 28 day subacute toxicity studies following demonstration of the feasibility of such an approach (Hamada et al., 2001; Krishna et al., 1998; Madrigal-Bujaidar et al., 2008). The evidence from one evaluation of micronucleus tests conducted on samples from short-term, subchronic and from a few chronic studies in mice has been published (Witt et al., 2000). In mice, MN in polychromatic erythrocytes represent DNA damage

occurring in the last 72h, whilst MN in normochromatic erythrocytes represent average damage during the 30 day period prior to sampling (Witt et al., 2000).

95-96. The development of a simultaneous liver and peripheral blood micronucleus assay in adult rats has also been reported (Suzuki et al., 2005). A correlation between micronucleus induction in hepatocytes and hepatocarcinogenicity was shown and the authors proposed that the assay could detect micronucleus-inducing chemicals that require metabolic activation. Takasawa et al. (2007), Suzuki et al., (2009) and Hamada et al. (2015) have also reported developments of an *in vivo* liver micronucleus assay, which has been discussed by IWGT (Uno et al., 2015b; Kirkland et al., 2019b), and it has been recommended that an OECD guideline should be developed.

96-97. *Transgenic Rodent Mutation (TGR) Assay for Gene Mutations* The transgenic rodent somatic and germ cell gene mutation assays (OECD Test Guideline ^[RB62] 488: Transgenic Rodent Somatic and Germ Cell Gene Mutation Assays) (OECD, OECD, 2020b)^[OS63] can be used to assess gene mutations in a wide range of rodent tissues (including germ cells) using all routes of administration and is particularly valuable when investigating gene mutation as the genotoxic endpoint (Kirkland et al., 2019^{a, b}). There are sufficient data to support the use of the Muta™ mouse, BigBlue® mouse and rat (including use of λ cII transgene), *LacZ* plasmid mouse, and the *gpt* delta mouse ^[DK64]^[RB65] models in TG 488.

97-98. Molecular sequencing of induced mutations in transgenic targets can aid in interpretation of study results (particularly equivocal responses) and also provide mechanistic information. The OECD published a Detailed Review Paper (DRP) on Transgenic Rodent Gene Mutation Assays which led to the development of an OECD guideline that was adopted in July 2011, with revision in 2013 (OECD, 2013) and in 2020 (OECD, 2020b).^[DK66]^[RB67] The latest version focuses on updating recommended regimes for the analysis of mutations in germ cells (discussed fully in the COM document 'Test Strategies for Germ Cell Mutagens' (COM, 202^x)). TG488 states that "when both somatic and germ cells need to be collected and/or tested, based on regulatory requirements, or toxicological information, a 28+28d regimen [i.e. 28 days treatment with sampling 28 days following administration of the final dose] permits the testing of mutations in somatic tissues and tubule germ cells from the same animals".

Rodent Comet Assay for DNA Damage

98-99. The *in vivo* comet assay (OECD TG 489: In Vivo Mammalian Alkaline Comet Assay) (OECD, 2016b) detects a wide spectrum of DNA damage including repairable DNA damage. A report of an international validation of the *in vivo* alkaline comet assay has been published (Uno et al., 2015a) and formed the basis for the OECD guideline.

An overview of the types of genetic lesions detected is given above in paragraph 71. The *in vivo* comet assay can detect chemicals that induce gene mutations and has produced positive results for nearly 90% of rodent carcinogens not detected by the rodent BMMN assay (Kirkland and Speit, 2008). It also shows high sensitivity when compared with TGR results in liver and the GI tract, and high sensitivity at detecting bacterial mutagens and mutagenic carcinogens (Kirkland et al., 2019a, b). Developments regarding the conduct of the *in vivo* alkaline comet assay were detailed in the previous COM guidance (COM, 2011). This assay can be used for elucidating positive *in vitro* genotoxicity findings and to evaluate genotoxicity in target organs of toxicity (Hartmann et al., 2004), however, it would not be an appropriate follow-up for a chemical causing aneuploidy *in vitro*. The comet assay can be applied to a wide range of species and in many tissues including site-of-contact tissues. In the absence of data indicating particular tissues of interest (e.g. toxic findings or tissue accumulation seen in other studies), the IWGT concluded that comet analysis of the liver combined with the bone marrow or peripheral blood micronucleus assay will be sufficient in most cases. However, if systemic exposure is expected, or found, to be low then site-of-contact-effects in GI tract are effective (Kirkland, 2019b). Validation of a protocol for a germ cell comet assay is ongoing (paragraph 91).

99-100. The Committee considers that the *in vivo* comet assay has appropriate sensitivity to detect chemicals which induce both gene mutations and/or clastogenicity. Thus the *in vivo* comet assay is recommended as a core test in the initial *in vivo* genotoxicity testing strategy to assess DNA damage in multiple somatic tissues in a single study. It is possible to include the comet assay within other *in vivo* genotoxicity tests (Vasquez, 2010) or within standard subacute or subchronic regulatory toxicity tests (Rothfuss et al., 2010), although the logistics of achieving the correct sampling time in relation to the final doses must be carefully considered (Speit et al., 2015).

Non-Core In Vivo Test: Rat Liver UDS Assay for DNA Damage

100-101. The rodent liver UDS assay is an established approach for investigating genotoxic activity in the liver with the endpoint measured being indicative of DNA damage and subsequent repair in liver cells. The COM consideration of this assay and published evaluations now suggest it is less sensitive than the *in vivo* comet assay with regard to identification of genotoxicity in the liver. An analysis of the prediction of rodent carcinogens not identified by the micronucleus tests indicated that the comet assay was considerably better than the rat liver UDS assay at identifying rodent carcinogens (Kirkland and Speit, 2008; Speit et al., 2015). Based on these analyses, EFSA concluded that the UDS assay was of limited usefulness in genotoxicity testing

strategies, being only suitable for the detection of chemicals causing damage in the liver, and with a lower predictive value than the TGR and comet assays in detecting chemicals which cause gene mutations. For existing datasets, where the UDS assay has been used as a follow up to positive *in vitro* gene mutation findings, a UDS study is considered adequate only for positive results (Hardy et al., 2017). The COM agree with this opinion and recommend use of the comet assay rather than rodent liver UDS in order to assess potential for DNA damage *in vivo*.

~~401-102.~~ Another non-core test involves the detection of gene mutations at the endogenous phosphatidylinositol glycan complementation group A gene (*Pig-A*), a reporter gene in which mutations are currently detected in peripheral red blood cells of mammals (Bryce et al., 2008b; Dertinger et al., 2011; Miura et al., 2009). This assay has potential advantage of integration into regulatory toxicity tests (Dertinger et al., 2010; Khanal et al., 2018) and it is noted that *Pig-A* mutations increase with duration of dosing (Miura et al., 2009). The disadvantage of the assay is that, to date, only limited types of cells (red blood cells/ reticulocytes and male rat germ cells) have been used. It is anticipated that further developments and validation will lead to the development of an OECD Guideline. ^[RB68]

Discussion of Stage 2-Supplementary Tests.

~~402-103.~~ Supplementary *in vivo* genotoxicity tests need to be considered on a case-by-case basis taking into account all relevant information. It is considered that for most chemicals, supplementary *in vivo* genotoxicity data should be unnecessary but on a case-by-case basis, specific aspects of MoA (e.g. nature of DNA adducts) and further ^[RB69] characterisation of germ cell genotoxicity (e.g. characterisation of male and/or female germ cell clastogenicity including use of FISH, and the evaluation of heritable effects) may be required. DNA adduct studies can provide valuable information on potential genotoxicity as a follow up for *in vitro* mutagens which have yielded negative results in *in vivo* genotoxicity assays (Phillips et al., 2000). DNA adduct data (including type of adduct, frequency, persistence, repair process) can be used to inform on MoA and its relationship to carcinogenesis, and should be considered in conjunction with other relevant data such as dosimetry, toxicity, genotoxicity and tumour data (Jarabek et al., 2009).

~~403-104.~~ A brief outline of these additional Stage 2 methods is given in Table 1 below. Reference is also made in Table 1 to a number of tests for heritable genotoxic effects but it is noted that these tests, which involve the use of many animals and demand a high level of expertise, are comparatively rarely used. The COM is aware that there is the possibility that gender differences in germ cell mutagenesis may exist

DRAFT DOCUMENT FOR DISCUSSION

1195 and this aspect may need to be considered on a case-by-case basis (Eichenlaub-Ritter
1196 et al., 2007). The conclusions of COM's evaluation of germ cell testing methods are
1197 provided in a separate document (COM, 202~~x~~).

1198

1199

Table 1 Supplementary in vivo genotoxicity tests [RB70]

Assay	Endpoint	Guidance	Main Attributes	Comments
Investigations of DNA Adducts				
³² P-postlabelling	DNA adducts	IWGT	Can be highly sensitive particularly with bulky adducts and if appropriate enrichment technique used.	Interpretation of results can be complex. Involves handling high-activity ³² P. (Phillips et al., 2000)
Covalent binding to DNA A variety of methods can be used such as those involving radioactive decay measurements (eg. ¹⁴ C-) or isotope measurements (eg Accelerator Mass Spectrometry AMS)	DNA Adducts	IWGT	Some methods (AMS) are potentially very sensitive and can provide data on DNA binding at levels of exposure similar to low level environmental exposures	Uses radiolabelled compound [DK71][RB72](very small amounts (e.g. nanograms) in the case of AMS). Interpretation of results can be complicated (e.g. by non-specific binding). (Himmelstein et al., 2009)
Supplementary investigations of germ cell mutagenicity				
Analysis for clastogenicity/aneuploidy	Structural and numerical changes in spermatogonia, spermatocytes or oocytes	OECD	Can provide information on nature of effects in spermatogonia, spermatocytes and/or oocytes of mice or rats	Can provide useful information on MeGAMoA. (Russo, 2000)
Spermatid micronucleus assay	Chromosomal aberrations and or lagging chromosomes	None available	Provides information of clastogenic and/or aneugenic effects in spermatocytes.	(Allen et al., 2000)
Dominant lethal assay	Chromosomal/gene mutations	OECD	Provides information on unstable chromosomal changes in gametes that lead to fetal death after fertilization and can determine stage(s) of gametogenesis affected	Little used. needs relatively large numbers of animals (Adler et al., 1994)
Mouse specific locus test	Gene mutations	EPA	Provides information on genetic changes transmitted to the first generation progeny as basis for estimation of induced mutation frequency in humans	Very rarely used. Needs large numbers of animals (Adler, 2008)
Mouse heritable translocation test	Chromosomal changes	EPA	Provides information on chromosomal changes transmitted to the first generation progeny as basis for estimation of induced translocation frequency in humans	Very rarely used. Needs large numbers of animals (Adler, 2008)
Sperm Comet assay	Double strand breaks and/or apurinic sites in sperm head DNA	None available	Provides information on genetic instability in sperm	(Trivedi et al., 2010)
Spermatid UDS assay	Repair DNA synthesis in spermatocytes	EPA	Provides information on induction of DNA lesions	(Sotomajor and Sega, 2000)

1200

1201

Summary Stage 2 (*In Vivo* Genotoxicity Testing)

~~104-105.~~ The *in vivo* genotoxicity testing strategy has to be designed on a case-by-case basis and can be used to address aspects of *in vivo* mutagenicity, for example;

- Investigation of key end point(s) identified in Stage 1,
- Investigation of genotoxicity in tumour target tissue(s),
- Investigation of potential for germ cell genotoxicity,
- Investigation of *in vivo* genotoxic potential for chemicals which were negative in Stage 1 but where there is high or moderate and prolonged exposure.
- Investigation of genotoxicity in site of contact tissues.

~~105-106.~~ The recommended *in vivo* genotoxicity test(s) include micronucleus assay, bone marrow cytogenetics, comet assay in rodents and transgenic rodent mutation assay. In some instances there may be a need to undertake more than one *in vivo* test to perform an initial assessment of *in vivo* genotoxic potential (e.g. where endpoints cannot be assessed in one study and there is a need to investigate multiple end points before reaching conclusions on *in vivo* mutagenic potential). Multiple endpoints may be combined in a single study. If positive results are obtained it is important to consider the evidence for genotoxic mode of action and check the data for evidence of irrelevant positive results. Usually negative results obtained in a carefully selected *in vivo* test (possibly studying more than one endpoint and tissue) will be sufficient to address positive results found *in vitro*, provided that target tissue exposure is sufficient. However, a further test(s) may be needed if some of the genotoxic effects seen in Stage 1 *in vitro* tests had not been adequately studied *in vivo* (e.g. the chemical affects multiple mutagenic end-points), or other aspects of the genotoxic potential of the chemical had not been fully resolved (e.g. in the case where an investigation of heritable effects was required). If equivocal results are obtained, then supplementary testing (including scoring of additional cells in the case of the comet and MN assays) [DK73][RB74] may be needed. This may involve repeating some aspects of the recommended *in vitro* and/or *in vivo* genotoxicity tests or performing additional investigations (e.g. MoA investigations, such as DNA adducts and/or more detailed consideration of heritable effects). The supplementary *in vivo* genotoxicity testing strategy should be devised on a case-by-case basis. There is a need to select the most appropriate assay(s) on a case-by-case basis. All relevant factors such as results from previous tests, structural alerts and available information on toxicokinetics, tissue toxicity and metabolism of the chemical, should be considered. In the absence

of appropriate germ cell genotoxicity data, the COM considers it is reasonable to assume that all somatic cell mutagens have the potential to be germ cell mutagens.


Possible Future Developments

~~106-107.~~ The COM is aware that new assays and toxicogenomic approaches are under development which might be of value within genotoxicity testing. The ToxTracker assay uses a series of reporter cell lines expressing biomarker genes selected to detect chemically induced DNA damage and oxidative stress [DK75][RB76] (Hendriks et al., 2012; Hendriks et al., 2011; Brandsma et al., 2020). Whilst the assay presents an interesting approach to identifying MoA, it is not currently considered to be a reliable genotoxicity test and is more suitable as a biomarker assay or in MoA investigations.

~~107-108.~~ Other potential tests include investigation of instability in expanded simple tandem repeats in male gametes and offspring to evaluate heritable mutations (Singer et al., 2006). The development of new high throughput assays for the assessment of germ line mutations and the quantification of risk from such data may provide opportunities to protect future generations from mutated DNA sequences. Developments within the field of toxicogenomics are also likely to provide new methods for investigating genotoxic mechanisms and informing on MoA. The COM have reviewed data generated in this field several times during 2008 and 2009 up to the drafting of this guidance statement but currently conclude that the evidence does not support the routine use of toxicogenomic approaches as an adjunct to genotoxicity testing.

~~108-109.~~ HESI-GTTC has considered 'next generation' testing strategies for genotoxicity including the use of QSAR modelling, MoA assessments and their human relevance. The concept of quantitative assessment of genotoxicity data was also discussed (Gollapudi et al., 2013, 2014; Johnson et al., 2014; Dearfield et al., 2017)[DK77][RB78]. Quantitative approaches to the assessment of genotoxicity data was considered by COM in 2017-2018. Their conclusions were published in a statement (<https://www.gov.uk/government/publications/quantitative-approaches-to-the-assessment-of-genotoxicity-data>). IWGT have also published guidance on quantitative approaches to genotoxicity risk assessment (MacGregor et al., 2015a, b).

Figure 1: Overview of Strategy for testing chemical substances for genotoxicity



1266
1267
1268

[DK79][RB80]

Figure 2: Screening (Stage 0) and *in vitro* tests (Stage 1)

Figure 3: *In vivo* tests (Stage 2)^[RB81]

References

References^[RB82](

- Aardema, M., Albertini, S., Arni, P., Henderson, L., Kirsch-Volders, M., Mackay, J., Sarraf, D., Stringer, D., and Taalman, R. (1998). Aneuploidy: a report of an ECETOC task force *Mutation Research* 410, 3-79.
- Aardema, M., Snyder, R., Spicer, C., Divi, K., Morita, T., Mauthe, R., Gibson, D., Soelter, S., Curry, P., Thybaud, V., *et al.* (2006). SFTG international collaborative study on *in vitro* micronucleus test. III. Using CHO cells. *Mutation Research* 607, 61-87.
- Aardema, M.J., Barnett, B.B., Mun, G.C., Dahl, E.L., Curren, R.D., Hewitt, N.J. and Pfuhler, S. (2013). Evaluation of chemicals requiring metabolic activation in the EpiDerm™ 3D human reconstructed skin micronucleus (RSMN) assay. *Mutation Research* 750, 40-49.
- Ackerman, J., Sharma, R., Hitchcock, J., Hayashi, T., Nagai, Y., Li, S., Lu, S., Miret, J., Tang, K., Spence, F., *et al.* (2009). Inter-laboratory evaluation of the bioluminescent Salmonella reverse mutation assay using 10 model chemicals. *Mutagenesis* 24, 433-438.
- Adler, I.-D. (2008). Mutagenicity Tests *in vivo*. In Toxicology and Risk Assessment H. Grein, Snyder, R., ed. (Wiley and Sons, UK), pp. pp371-384.
- Adler, I., Shelby, M., Bootman, J., Favor, J., Generoso, W., Pacchierotti, F., Shibuya, T., and Tanaka, N. (1994). Summary report of the Working Group on Mammalian Germ Cell Tests. *Mutation Research* 312, 313-318.
- Allen, J.W., Collins, B.W., Lan, A., Afshari, A.J., George, M.H., DeAngelo, A.B., and Fuscoe, J.C. (2000). Erythrocyte and spermatid micronucleus analyses in mice chronically exposed to potassium bromate in drinking water. *Environmental and Molecular Mutagenesis* 36, 250-252.
- Andres, E., Molinari, J., Remoué, N., Sá-Rocha, V. M., Barrichello, C., & Hurtado, S. P. (2012). Successful micronucleus testing with the EPI/001 3D reconstructed epidermis model: preliminary findings. *Mutation research*, 743(1-2), 36–41.
- Ashby, E., and Paton, D. (1993). The influence of chemical structure on the extent and sites of carcinogenesis for 522 rodent carcinogens and 55 different human carcinogen exposures *Mutation Research* 286, 3-74.
- Attia, S., Badary, O., Hamada, S., de Angelis, M., and Adler, I. (2005). Othovanadate increased the frequency of aneuploid mouse sperm without micronucleus induction in mouse bone marrow erythrocytes at the same dose level. *Mutation Research* 583, 158-167.
- Aubrecht, J., Osowski, J., Persaud, P., Cheung, J., Ackerman, J., Lopes, S., and Ku, W. (2007). Bioluminescent Salmonella reverse mutation assay: a screen for detecting mutagenicity with high throughput attributes. *Mutagenesis* 22, 335-342.

- 311 [Barcham, R., Orsini, N., Andres, E., Hundt, A., & Luzy, A. P. \(2018\). Successful proof of concept of a](#)
312 [micronucleus genotoxicity assay on reconstructed epidermis exhibiting intrinsic metabolic](#)
313 [activity. *Mutation research. Genetic toxicology and environmental mutagenesis*, 829-830, 75–86.](#)
- 1314 Benfenati, E., Benigni, R., Demarini, D., Helma, C., Kirkland, D., Martin, T., Mazzatorta, P., Ouédraogo-
1315 Arras, G., Richard, A., Schilter, B., *et al.* (2009). Predictive models for carcinogenicity and mutagenicity:
1316 frameworks, state-of-the-art, and perspectives. *J Environ Sci Health C Environ Carcinog Ecotoxicol Rev*.
1317 27, 57-90.
- 1318 Benigni, R., and Bossa, C. (2008). Structure alerts for carcinogenicity, and the Salmonella assay system:
1319 a novel insight through the chemical relational databases technology. *Mutation Research* 659, 248-261.
- 1320 Benigni, R., Bossa, C., and Worth, A. (2010). Structural analysis and predictive value of the rodent *in*
1321 *vivo* micronucleus assay. *Mutagenesis e-pub March 1*, 1-7.
- 1322 Benigni, R., Netzva, T., Benfenati, E., Bossa, C., Franke, R., Helma, C., Hulzebos, E., Marchant, C.,
1323 Richard, A., Woo, Y.-T., *et al.* (2007). The Expanding Role of Predictive Toxicology: An Update on the
1324 (Q)SAR Models for Mutagens and Carcinogens. *Journal of Environmental Science, Health C Environ*
1325 *Carcinog Ecotoxicol Rev*. 25, 53-97.
- 1326 Birrell, L., Cahill, P., Hughes, C., Tate, M., and Walmsley, R. (2010). AM recommended lists of
1327 genotoxic and non-genotoxic chemicals for assessment of new genotoxicity tests. *Mutation Research*
1328 695, 87-95.
- 1329 Bishop, J. (2003). Female specific reproductive toxicities following preconception exposure to
1330 xenobiotics. *Advances in Experimental Medicine* 518, 1-9.
- 1331 Blakey, D., Galloway, S., Kirkland, D., and MacGregor, J. (2008). Regulatory aspects of genotoxicity
1332 testing: from hazard identification to risk assessment. *Mutation Research* 657, 84-90.
- 1333 Bowen, D., Whitwell, J., Lillford, L., Henderson, D., Kidd, D., McGarry, S., Pearce, G., Beevers, C.,
1334 and Kirkland, D. (2010). Validation of a multi-endpoint assay in rats: Bone marrow micronucleus, comet
1335 and flow cytometric peripheral blood micronucleus. *Mutation Research* (accepted for publication).
- 1336 Bowen, D., Whitwell, JH, Lillford, L, Henderson, D, Kidd, D, McGarry, S, Pearce, G, , and Beevers,
1337 C., Kirkland, DJ; (2011). Evaluation of a multi-endpoint assay in rats, combining the bone-marrow
1338 micronucleus test, the Comet assay and the flow-cytometric peripheral blood micronucleus test. *Mutation*
1339 *Research* 722, 7-19.
- 1340 Brambilla, G., and Martelli, A. (2004). Failure of the standard battery of short-term tests in detecting
1341 some rodent and human genotoxic carcinogens. *Toxicology* 196, 1-19.
- 1342 [Brandsma, I., Moelijker, N., Derr, R., Hendriks, G. \(2020\) Aneugen Versus Clastogen Evaluation and](#)
1343 [Oxidative Stress-Related Mode-of-Action Assessment of Genotoxic Compounds Using the ToxTracker](#)
1344 [Reporter Assay. *Toxicological Sciences*, 177, 202–213.](#) Bryce, S., Avlasevich, S., Bemis, J.,
1345 Lukamowicz, M., Elhajouji, A., Van Goethem, F., De Boeck, M., Beerens, D., Aerts, H., van Gompel,
1346 J., *et al.* (2008a). Interlaboratory evaluation of a flow cytometric, high content *in vitro* micronucleus
1347 assay. *Mutation Research* 650, 181-195.
- 1348 Bryce, S., Bemis, J., Avlasevich, S., and Dertinger, S. (2007). *In vitro* micronucleus assay scored by flow
1349 cytometry provides a comprehensive evaluation of cytogenetic damage and cytotoxicity. *Mutation*
1350 *Research* 78-91.
- 1351 Bryce, S., Bemis, J., and Dertinger, S. (2008b). *In vivo* Mutation Assay based on the Endogenous *Pig-a*
1352 Locus. *Environmental and Molecular Mutagenesis* 49, 256-264.
- 1353 Bryce, S., Shi, J., Nicolette, J., Diehl, M., Sonders, P., Avlasevich, S., Raja, S., Bemis, J., and Dertinger,
1354 S. (2010). High Content Flow Cytometric Micronucleus Scoring Method is Applicable to Attachment
1355 Cell Lines. *Environmental and Molecular Mutagenesis* 51, 260-266.

- 1356 Burlinson, B., Tice, R., Speit, G., Agurell, E., Brendler-Schwaab, S., Collins, A., Escobar, P., Honma,
1357 M., Kumaravel, T., Nakajima, M., *et al.* (2007). Fourth International Workgroup on Genotoxicity testing:
1358 Results of the *in vivo* Comet assay workgroup. *Mutation Research* 627, 31-35.
- 1359 Cariello, N., Wilson, J., Britt, B., Wedd, D., Burlinson, B., and Gombar, V. (2002). Comparison of the
1360 computer programs DEREK and TOPKAT to predict bacterial mutagenicity. *Mutagenesis* 17, 321-329.
- 1361 Chapman, K, Thomas A, Wills, J, Pfuhler, S, Doak, S, Jenkins G. (2014) Automation and validation of
1362 micronucleus detection in the 3D EpiDerm™ human reconstructed skin assay and correlation with 2D
1363 dose responses. *Mutagenesis* 29, 165-175.
- 1364 Cimino, M. (2006). Comparative Overview of Current International Strategies and Guidelines for
1365 Genetic Toxicology Testing for Regulatory Purposes. *Environmental and Molecular Mutagenesis* 47,
1366 362-390.
- 1367 Ciranni, R., Antonetti, M., and Miglore, L. (1995). Vanadium salts induce cytogenetic effects in *in vivo*
1368 treated mice. *Mutation Research* 343, 53-60.
- 1369 Clare, M., Lorenzon, G., Akhurst, L., Marzin, D., van Delft, J., Montero, R., Botta, A., Bertens, A.,
1370 Cinelli, S., Thybaud, V., *et al.* (2006). SFTG international collaborative study on *in vitro* micronucleus
1371 test II. Using human lymphocytes. *Mutation Research* 607, 37-60.
- 1372 Clarke, J, Lawlor, T, Madraymootoo, W, Pant, K, Young, R, Wagner, V, 3rd, Aardema, M. (2012).
1373 Summary of *in vitro* genetic toxicology assay results: Expected and unexpected effects of recent study
1374 design modifications. *Environ Mol Mutagen* 53, 631–635.
- 1375 Claxton, L., Stewart-Hook, V., and Warren, S. (2001). Methods for the Spiral *Salmonella* mutagenicity
1376 assay including specilaised applications. . *Mutation Research* 488, 241-257.
- 1377 Clements, J. (2000). The Mouse Lymphoma Assay. *Mutation Research* 455, 97-110.
- 1378 Combes, R., Grindon, C., Cronin, M., Roberts, D., and Garrod, J. (2007). Proposed Integrated Decision-
1379 tree Testing Strategies for Mutagenicity and Carcinogenicity in Relation to the EU REACH Legislation.
1380 *ATLA* 35, 267-287.
- 1381 Contrera, J., Mathews, E., Kruhlak, N., and Benz, R. (2005). *In silico* screening of Chemicals for
1382 Bacterial Mutagenicity Using Electropological E-state indices and MDL QSAR Software. *Regulatory*
1383 *Toxicology Pharmacology* 43, 313-323.
- 1384 Contrera, J., Matthews, E., Kruhlak, N., and Benz, R. (2008). *In silico* Screening of Chemicals for
1385 Genetic Toxicity Using MDL-QSA, Nonparametric Discriminant Analysis, E-State, Connectivity and
1386 Molecular Property Descriptors. *Toxicology Mechanisms and Methods* 18, 207-216.
- 1387 Corvi, R., Albertini, S., Hartung, T., Hoffman, S., Muaurici, D., Pfuhler, S., van Benthem, J., and
1388 Vanparys, P. (2008). ECVAM retrospective validation of the *in vitro* micronucleus test (MNT).
1389 *Mutagenesis* 23, 271-283.
- 1390 CSGMT (1995). The Collaborative Study Group for the Micronucleus Test (CSGMT)¹
1391 (CSGMT/JEMS.MMS, The Mammalian Study Group of the Environmental Mutagen Society of Japan).
1392 Protocol recommended by the CSGMT/JEMS.MMS for the short-term mouse peripheral blood
1393 micronucleus test. *Mutagenesis* 10, 153-159.
- 1394 Curren, R., Mun, G., Gibson, D., and Aardema, M. (2006). Development of a method for assessing
1395 micronucleus induction in a 3D human skin model (EpiDerm™). *Mutation Research* 607, 192-204.
- 1396 Custer, L., and Sweder, K. (2008). The role of Genetic Toxicology in Drug Discovery and Optimization.
1397 *Current Drug Metabolism*. 9, 978-985.

- De Boeck, M., van der Leede, B., Van Goethem, F., De Smedt, A., Steemans, M., A., L., and Vanparys, P. (2005). Flow cytometric analysis of micronucleated reticulocytes: Time- and dose-dependent response of known mutagens in mice, using multiple blood sampling. *Environmental Molecular Mutagenesis* 46, 30-42.
- Dean, S., Brooks, T., Burlinson, B., Mirsalis, J., Myhr, B., Recio, L., and Thybaud, V. (1999). Transgenic mouse mutation assay systems can play an important role in regulatory mutagenicity testing for *in vivo* for the detection of site-of-contact mutagens. *Mutagenesis* 14, 141-151.
- Dearfield, K., Thybaud, V., Cimino, M., Custer, L., Czich, A., Harvey, J., Hester, S., Kim, J., Kirkland, D., Levy, D., *et al.* (2010). Follow-up Actions from Positive Results of *In Vitro* Genetic Toxicology Testing.
- Dearfield, K.L., Gollapudi, B.B., Bemis, J.C., Benz, R.D., Douglas, G.R., Elespuru, R.K., Johnson, G.E., Kirkland, D.J., LeBaron, M.J., Li, A.P., *et al.* (2017). Next generation testing strategy for assessment of genomic damage: A conceptual framework and considerations. *Environ Mol Mutagen* 58, 264-283.
- Decordier, I., Papine, A., Plas, G., Roesems, S., Vande Loock, K., Moreno-Palomo, J., Cemeli, E., Anderson, D., Fucic, A., Marcos, R., *et al.* (2009). Automated image analysis of cytokinesis-blocked micronuclei: an adapted protocol and a validated scoring procedure for biomonitoring. *Mutagenesis* 24, 85-93.
- Dertinger, S., Phonetheswath, S., Franklin, D., Weller, P., Torous, D., Bryce, S., Avlasevich, S., Bemis, J., Hyrien, O., Palis, J., *et al.* (2010). Integration of mutation and chromosomal damage endpoints into 28-day repeat dose toxicology studies. *Toxicological Sciences* 115, 401-411.
- Dertinger, S.D., Bryce, S.M., Phonetheswath, S., and Avlasevich, S.L. (2011). When pigs fly: immunomagnetic separation facilitates rapid determination of *Pig-a* mutant frequency by flow cytometric analysis. *Mutation Research*. 721, 163-170.
- DOH (1989). Department of Health. Report on Health and Social Subjects, 35. Guidelines for the testing of chemicals for Mutagenicity. Committee on Mutagenicity of Chemicals in Food, Consumer Products and the Environment. London, HMSO.
- DOH (2000). Department of Health. Guidance for the testing of chemicals for Mutagenicity. Committee on Mutagenicity of Chemicals in Food, Consumer Products and the Environment.
- DOH (2011). Department of Health. Guidance on a strategy for genotoxicity testing of chemicals. Committee on Mutagenicity of Chemicals in Food, Consumer Products and the Environment..Eastmond, D., Hartwig, A., Anderson, D., Anwar, W., Cimino, M., Dobrev, I., Douglas, G., Nohmi, T., Phillips, D., and Vickers, C. (2009). Mutagenicity testing for chemical risk assessment: update of the WHO/IPCS Harmonised Scheme. *Mutagenesis* 24, 341-349.
- ECHA (2017). Guidance on Information Requirements and Chemical Safety Assessment Chapter R.7a: Endpoint specific guidance, version 6. July 2017 R.7.7 Available from : https://www.echa.europa.eu/documents/10162/13632/information_requirements_r7a_en.pdf/e4a2a18f-a2bd-4a04-ac6d-0ea425b2567f
- EFSA (2011). Scientific opinion on genotoxicity testing strategies applicable to food and feed safety assessment. *EFSA Journal* 9, 2379. <https://www.efsa.europa.eu/en/efsajournal/pub/2379>.
- EFSA Scientific Committee, Hardy A, Benford D, Halldorsson T, Jeger M, Knutsen HK, More S, Naegeli H, Noteborn H, Ockleford C, Ricci A, Rycken G, Silano V, Solecki R, Turck D, Younes M, Aquilina G, Crebelli R, Gurtler R, Hirsch-Ernst KI, Mosesso P, Nielsen E, van Benthem J, Carf M, Georgiadis N, Maurici D, Parra Morte J and Schlatter J, (2017). Scientific Opinion on the clarification of some aspects related to genotoxicity assessment. *EFSA Journal* 2017;15(12):5113, 25 pp. Available: <https://www.efsa.europa.eu/en/efsajournal/pub/5113>.

DRAFT DOCUMENT FOR DISCUSSION

- 1443 Eichenlaub-Ritter, U., Adler, I., Carere, A., and Pacchierotti, F. (2007). Gender differences in germ cell
1444 mutagenesis and genetic risk. *Environmental Research* 104, 22-36.
- 1445 Elespuru, R.A., R. Atrakchi, AH. Bigger, CA. Heflich, RH. Jagannath, DR. Levy., and DD. Moore, M.O.,
1446 Y, Robison, TW, Sotomayor, RE, Cimino, MC, Dearfield KL. (2009). Current and future application of
1447 genetic toxicity assays: the role and value of *in vitro* mammalian assays. *Toxicological Sciences* 109,
1448 172-179.
- 1449 Emmert, B., Bunger, J., Keuch, K., Muller, M., Emmert, S., Hallier, E., and Westphal, G. (2006).
1450 Mutagenicity of cytochrome P450 2E1 substrates in the Ames test with metabolic component *S.*
1451 *tymphimurium* strain YG7108pin3ERb₅. *Toxicology* 228, 66-76.
- 1452 Escobar, P.A., Kemper, R.A., Tarca, J., Nicolette, J., Kenyon, M., Glowienke, S., Sawant, S.G.,
1453 Christensen, J., Johnson, T.E., McKnight, C., Ward, G., Galloway, S.M., Custer, L., Gocke, E.,
1454 O'Donovan, M.R., Braun, K., Snyder, R.D., Mahadevan, B. (2013). Bacterial mutagenicity screening in
1455 the pharmaceutical industry. *Mutation Research/Reviews in Mutation Research* 752, 99-118.
- 1456 Fellows, M., O'Donovan, M., Lorge, E., and Kirkland, D. (2008a). Comparison of different methods for
1457 an accurate assessment of cytotoxicity in the *in vitro* micronucleus test II. Practical aspects with toxic
1458 agents. *Mutation Research* 655, 4-21.
- 1459 Fellows, M., O'Donovan, M., Lorge, E., and Kirkland, D. (2008b). Comparison of different methods for
1460 an accurate assessment of cytotoxicity in the *in vitro* micronucleus testII: Practical aspects with toxic
1461 agents. *Mutation Research* 655, 4-21.
- 1462 Fellows, M.D., Boyer, S., and O'Donovan, M.R. (2011a). The incidence of positive results in the mouse
1463 lymphoma TK assay (MLA) in pharmaceutical screening and their prediction by MultiCase MC4PC. .
1464 *Mutagenesis* 26, 529-532.
- 1465
1466 Fellows, M.D., Doherty, A.T., Priestley, C.C., Howarth, V. and O'Donovan, M.R. (2011b). The ability
1467 of the mouse lymphoma TK assay to detect aneugens. *Mutagenesis* 26, 771-781.
- 1468 Fenech, M. (2006). Cytokinesis-block micronucleus assay evolves into a 'cytome' assay for chromosomal
1469 instability, mitotic dysfunction and cell death. *Mutation Research* 600, 58-66.
- 1470 Fenech, M. (2007). Cytokinesis-block micronucleus assay. *Nature Protocols* 2, 1084-1104.
- 1471 Fischer, S.J., Benson, L.M., Fauq, A., Naylor, S., and Windebank, A.J. (2008). Cisplatin and dimethyl
1472 sulfoxide react to form an adducted compound with reduced cytotoxicity and neurotoxicity. .
1473 *NeuroToxicology* 29, 444-452.
- 1474 Flamand, N., Marrot, L., Belaidi, J.-P., Bourouf, L., Dourille, E., Feltes, M., and Meunier, J.-R. (2006).
1475 Development of genotoxicity test procedures with Episkin® a reconstructed human skin model:
1476 Towards new tools for *in vitro* risk assessment of dermally applied compounds? *Mutation Research* 606,
1477 39-51.
- 1478 Fluckiger-Isler, S., Baumeister, M., Braun, K., Gervais, V., Hasler-Nguyen, N., Reimann, R., Van
1479 Gompel, J., Wunderlich, H.-G., and Engelhardt, G. (2004). Assessment of the performance of the Ames
1480 IITM assay: a collaborative study with 19 coded compounds. *Mutation Research* 558, 181-197.
- 1481 Fowler, P., Young, J., Jeffrey, L., Hand, T., Smith, K., Kirkland, D., Carmichael, P., and Pfuhler, S.
1482 (2012a). Reduction of misleading ("false") positive results in mammalian cell genotoxicity assays I.
1483 Choice of cell type. *Mutat Res.* 742, 11-25..
- 1484 Fowler, P., Young, J., Jeffrey, L., Hand, T., Smith, K., Kirkland, D., Carmichael, P., and Pfuhler, S.
1485 (2012b). Reduction of misleading ("false") positive results in mammalian cell genotoxicity assays II. The
1486 importance of cytotoxicity measure. *Mutat Res.* 747, 104-17.

DRAFT DOCUMENT FOR DISCUSSION

- 1487 Galloway, S. (2000). Cytotoxicity and Chromosome Aberrations *In Vitro*: Experience in Industry and the
1488 Case for an Upper Limit on Toxicity in the Aberration Assay. *Environmental and Molecular Mutagenesis*
1489 35, 191-201.
- 1490 Galloway, S., Lorge, E., Aardema, MJ, Eastmond, D, Fellows, M, Heflich, R, Kirkland, D., and Levy,
1491 D., Lynch, AM, Marzin, D, Morita, T, Schuler, M, Speit, G. (2011). Workshop summary: Top
1492 concentration for *in vitro* mammalian cell genotoxicity assays; and report from working group on toxicity
1493 measures and top concentration for *in vitro* cytogenetics assays (chromosome aberrations and
1494 micronucleus). *Mutation Research* 723 77-83.
- 1495 Garriott, M., Phelps, J., and Hoffman, W. (2002). A protocol for the *in vitro* micronucleus test I.
1496 Contributions to the development of a protocol suitable for regulatory submissions from an examination
1497 of 16 chemicals with different mechanisms of action and different levels of activity. *Mutation Research*
1498 517, 123-134.
- 1499 Gatehouse, D., Haworth, S., Cebula, T., Kier, L., Matsushima, T., Melcion, C., Nohmi, T., Ohta, T., and
1500 Venitt, S. (1994). Recommendations for the performance of bacterial mutation assays. *Mutation*
1501 *Research* 312, 217-233.
- 1502 Gealy, R., Wright-Bourque, J., Kraynak, A., McKelvey, T., Barnum, J., and Storer, R. (2007). Validation
1503 of a high-throughput *in vitro* alkaline elution/rat hepatocyte assay for DNA damage. *Mutation Research*
1504 629, 49-63.
- 1505 Glei, M., Hovhannisyan, G., and Pool-Zobel, B. (2009). Use of Comet-FISH in the study of DNA damage
1506 and repair: Review. *Mutation Research* 681, 33-43.
- 1507 [Gollapudi, B., Johnson, G., Hernandez, L., et al. \(2013\). Quantitative approaches for assessing dose-
1508 response relationships in genetic toxicology studies. *Environ. Mol. Mutagen.*, 54: 8-18.](#)
- 1509 Grant, S., Zhang, Y., Klopman, G., and Rosenkranz, H. (2000). Modeling the mouse lymphoma forward
1510 mutational assay: the Gene-Tox program database. . *Mutation Research* 465, 201-229.
- 1511 Hamada, S., Sutou, S., Morita, T., Wakata, A., Asanami, S., Hosoya, S., Ozawa, S., Kondo, K., Nakajima,
1512 M., Shimada, H., *et al.* (2001). Evaluation of the Rodent Micronucleus Assay by a 28-Day Treatment
1513 Protocol: Summary of the 13th Collaborative Study by the Collaborative Study Group for the
1514 Micronucleus Test (CSGMT)/Environmental Mutagen Society of Japan (JEMS)-Mammalian
1515 Mutagenicity Study Group (MMS). *Environmental and Molecular Mutagenesis* 37, 93-110.
- 1516 [Hamada, S., Ohyama, W., Takashima, R., Shimada, K., Matsumoto, K., Kawakami, S., Uno, F., Sui, H.,
1517 Shimada, Y., Imamura, T., Matsumura, S., Sanada, H., Inoue, K., Muto, S., Ogawa, I., Hayashi, A.,
1518 Takayanagi, T., Ogiwara, Y., Maeda, A., Okada, E., Terashima, Y., Takasawa, H., Narumi, K., Wako,
1519 Y., Kawasako, K., Sano, M., Ohashi, N., Morita, T., Kojima, H., Honma, M. and Hayashi, M. \(2015\).
1520 Evaluation of the repeated-dose liver and gastrointestinal tract micronucleus assays with 22 chemicals
1521 using young adult rats: summary of the collaborative study by the Collaborative Study Group for the
1522 Micronucleus Test \(CSGMT\)/The Japanese Environmental Mutagen Society \(JEMS\) - Mammalian
1523 Mutagenicity Study Group \(MMS\). *Mutat Res Genet Toxicol Environ Mutagen.* 780-781, 2-17.](#)
- 1524 Hartmann, A., Kiskinis, E., Fjallman, A., and Suter, W. (2001). Influence of cytotoxicity and compound
1525 precipitation on test results in the alkaline comet assay. . *Mutation Research* 497, 199-212.
- 1526 Hartmann, A., Schumacher, M., Plappert-Helberg, U., Lowe, P., Suter, W., and Mueller, L. (2004). Use
1527 of the alkaline *in vivo* Comet assay for mechanistic genotoxicity investigations. *Mutagenesis* 19, 51-59.
- 1528 Hastwell, P., Chai, L., Roberts, K., Webster, T., Harvey, J., Rees, R., and Walmsley, R. (2006). High-
1529 specificity and high sensitivity genotoxicity assessment in a human cell line: Validation of the
1530 GreenScreen HC GADD45a-GFP genotoxicity assay. *Mutation Research* 607, 160-175.
- 1531 Hayashi, M., Dearfield, K., Kasper, P., Lovell, D., Martus, H.J., and Thybaud, V. (2011). Compilation
1532 and use of genetic toxicity historical control data. *Mutat Res* 723, 87-90.

- Hayes, J.E., Doherty, A.T., Coulson, M., Foster, J.R., Cotton, P.T., and O'Donovan, M.R. (2013). Micronucleus induction in the bone marrow of rats by pharmacological mechanisms. I: glucocorticoid receptor antagonism. *Mutagenesis* 28, 227-232.
- Helleday, T., Johansson, F., and Jenssen, D. (2001). The DRAG Test: an Assay for Detection of genotoxic Damage. *ATLA* 29, 233-241.
- Hendriks, G., Atallah, M., Morolli, B., Calleja, F., Ras-Verloop, N., Huijskens, I., Raamsman, M., van de Water, B., and Vrieling, H. (2012). The ToxTracker assay: novel GFP reporter systems that provide mechanistic insight into the genotoxic properties of chemicals. *Toxicol Sci* 125, 285-298.
- Hendriks, G., Atallah, M., Raamsman, M., Morolli, B., van der Putten, H., Jaadar, H., Tijdens, I., Esveldt-van Lange, R., Mullenders, L., van de Water, B., *et al.* (2011). Sensitive DsRed fluorescence-based reporter cell systems for genotoxicity and oxidative stress assessment. *Mutat Res* 709-710, 49-59.
- Himmelstein, M., Boogaard, P., Cadet, J., Farmer, P., Kim, J., Martin, E., Persaud, R., and Shuker, D. (2009). Creating context for the use of DNA adduct data in cancer risk assessment: II. Overview of methods of identification and quantitation of DNA damage. *Critical Reviews in Toxicology*. 39, 679-694.
- Hiramoto, K., Nasuhara, A., Michikoshi, K., Kato, T., and Kikugawa, K. (1997). DNA strand-breaking activity and mutagenicity of 2,3-dihydro-3,5-dihydroxy-6-methyl-4-H-pyran-4-one (DDMP), a Maillard reaction product of glucose and glycine. *Mutation Research* 395 47-56.
- Hu, T., Kaluzhny, Y., Mun, G., Barnett, B., Karetzky, V., Wilt, N., Klausner, M., Curren, R., and Aardema, M. (2009). Intralaboratory and interlaboratory evaluation of the EpiDerm™ 3D human reconstructed skin micronucleus assay. *Mutation Research* 673, 100-108.
- ICH (2011). Guidance on Genotoxicity Testing and Data Interpretation for Pharmaceuticals Intended for Human Use . S2(R1) Available: <http://www.ich.org/products/guidelines/safety/article/safety-guidelines.html>
- ICH (2012). ICH guideline S2 (R1) on genotoxicity testing and data interpretation for pharmaceuticals intended for human use. Available: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/12/WC500119604.pdf.
- ICH (2014). Harmonised tripartite guideline on assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential cancer risk - M7. Available: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Multidisciplinary/M7/M7_Step_4.pdf [accessed Jan 2019].
- ICH (2015). Harmonised guideline - addendum to ICH M7: assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential cancer risk. Application of the principles of the ICH M7 guideline to calculation of compound-specific acceptable intakes - M7(R1). Available: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Multidisciplinary/M7/M7_Addendum_Step_2.pdf [accessed Jan 2019].
- Jagger, C., Tate, M., Cahill, P., Hughes, C., Knight, A.W., Billinton, N., and Walmsley, R.M. (2008). Assessment of the genotoxicity of S9-generated metabolites using the GreenScreen HC GADD45a-GFP assay. *Mutagenesis* 24, 35-50.
- Jarabek, A., Pottenger, L., Andrews, L., Casciano, D., Embry, M., Kim, J., Preston, J., Vijayaraj Reddy, M., Schoeny, R., Shuker, D., *et al.* (2009). Creating context for use of DNA adduct data in cancer risk assessment: I Data organization. *Critical Reviews in Toxicology* 39, 659-678.
- Johnson, G., Soeteman-Hernández, L., Gollapudi, B., *et al.* (2014), Derivation of point of departure (PoD) estimates in genetic toxicology studies and their potential applications in risk assessment. *Environ. Mol. Mutagen.*, 55: 609-623.

- 1579 Kamber, M., Fluckiger-Isler, S., Engelhardt, G., Jaeckh, R., and WZeiger, E. (2009). Comparison of the
1580 Ames II and the traditional Ames test responses with respect to mutagenicity, strain specificities, need
1581 for metabolism and correlation with rodent carcinogenicity. . *Mutagenesis* 24, 359-366.
- 1582 Kasper, P., Uno, Y., Mauthe, R., Asano, N., Douglas, G., Matthews, E., Moore, M., Mueller, L.,
1583 Nakajima, M., Singer, T., *et al.* (2007). Follow-up testing of rodent carcinogens not positive in the
1584 standard genotoxicity test battery: IWGT workgroup report. *Mutation Research* 627, 106-116.
- 1585 Kennelly, J., Water, R., Ashby, J., Lefevre, P., Burlinson, B., Benford, D., Dean, S., and Mitchell I, d.
1586 (1993). *In vivo* rat liver UDS assay. In *Supplementary Mutagenicity Tests*. UKEMS Report. Cambridge
1587 University Press pp 52-77.
- 1588 Khanal, S., Singh, P., Avlasevich, S.L., Torous, D.K., Bemis, J.C., and Dertinger, S.D. (2018).
1589 Integration of liver and blood micronucleus and Pig-a gene mutation endpoints into rat 28-day repeat-
1590 treatment studies: Proof-of-principle with diethylnitrosamine. *Mutat Res* 828, 30-35.
- 1591 Kirkland, D. (2010). Evaluation of different cytotoxic and cytostatic measures for the *in vitro*
1592 micronucleus test (MNVit). Summary of results of collaborative trial. *Mutation Research* 702, 139-147.
- 1593 Kirkland, D., Aardema, M., Henderson, L., and Muller, L. (2005a). Evaluation of the ability of a battery
1594 of three *in vitro* genotoxicity tests to discriminate rodent carcinogens and non-carcinogens 1. Sensitivity,
1595 specificity and relative predictivity. *Mutation Research* 584, 1-256.
- 1596 Kirkland, D., Henderson, L., Marzin, D., Muller, L., Parry, J., Speit, G., Tweats, D., and Williams, G.
1597 (2005b). Testing strategies in mutagenicity and genetic toxicology: An appraisal of the guidelines of the
1598 European Scientific Committee for Cosmetics and Non-Food Products for the evaluation of hair dyes.
1599 *Mutation Research* 588, 88-105.
- 1600 Kirkland, D., Aardema, M., Banduhn, N., Carmichael, P., Fautz, R., Meunier, J., and Pfuhler, S. (2007a).
1601 *In vitro* approaches to develop weight of evidence (WoE) and mode of action (MoA) discussions with
1602 positive *in vitro* genotoxicity results. *Mutagenesis* 22, 161-175.
- 1603 Kirkland, D., Hayashi, M., Jacobson-Kram, D., Kasper, P., MacGregor, J., Muller, L., and Uno, Y.
1604 (2007b). Summary of major conclusions from the 4th IWGT, San Francisco, 9-10 September, 2005.
1605 *Mutation Research* 627, 5-9.
- 1606 Kirkland, D., Pfuhler, S., Tweats, D., Aardema, M., Corvi, R., Darroudi, F., Elhajouji, A., Glatt, H.,
1607 Hastwell, P., Hayashi, M., *et al.* (2007c). How to reduce false positive results when undertaking *in vitro*
1608 genotoxicity testing and thus avoid unnecessary follow-up animal tests: Report of an ECVAM
1609 Workshop. *Mutation Research* 628, 31-55.
- 1610 Kirkland, D., and Speit, G. (2008). Evaluation of the ability of a battery of three *in vitro* genotoxicity
1611 tests to discriminate rodent carcinogens and non-carcinogens III. Appropriate follow-up testing *in vivo*.
1612 *Mutation Research* 654, 114-132.
- 1613 Kirkland, D., and Fowler, P. (2010). Further analysis of Ames-negative rodent carcinogens that are only
1614 genotoxic in mammalian cells at concentrations exceeding 1mM including retest of compounds of
1615 concern. *Mutagenesis* 25, 539-553.
- 1616 Kirkland, D., Reeve, L., Gatehouse, D., and Vanparys, P. (2011). A core *in vitro* genotoxicity battery
1617 comprising the Ames test plus the *in vitro* micronucleus test is sufficient to detect rodent carcinogens
1618 and *in vivo* genotoxins. *Mutation Research* 721, 27-73.
- 1619
1620 [Kirkland, D., Levy, D.D., LeBaron, M.J., Aardema, M.J., Beevers, C., Bhalli, J., Douglas, G.R., Escobar,](#)
1621 [P.A., Farabaugh, C.S., Guerard, M., Johnson, G.E., Kulkarni, R., Le Curieux, F., Long, A.S., Lott, J.,](#)
1622 [Lovell, D.P., Luijten, M., Marchetti, F., Nicolette, J.J., Pfuhler, S., Roberts, D.J., Stankowski Jr., L.F.,](#)
1623 [Thybaud, V., Weiner, S.K., Williams, A., Witt, K.L., and Young, R. \(2019a\). A comparison of transgenic](#)
1624 [rodent mutation and in vivo comet assay responses for 91 chemicals. *Mutat. Res.* 839, 21-35.](#)
1625

- [Kirkland, D., Uno, Y., Luijten, M., Beevers, C., van Benthem, J., Burlinson, B., Dertinger, S., Douglas, G.R., Hamada, S., Horibata, K., Lovell, D.P., Manjanatha, M., Martus, H-J., Mei, N., Morita, T., Ohyama, W., and Williams, A. \(2019b\). In vivo genotoxicity testing strategies: Report from the 7th International workshop on genotoxicity testing \(IWGT\). *Mutat. Res.* 847, 403035.](#)
- Kirsch-Volders, M., Sofuni, T., Aardema, M., Albertini, S., Eastmond, D., Fenech, M., Ishidate, M.J., Kirchner, S., Lorge, E., Morita, T., *et al.* (2003). Report from the in vitro micronucleus assay workshop group. *Mutation Research* 540, 153-163.
- Kirsch-Volders, M., Vanhauwaert, A., DeBoeck, M., and Decordier, I. (2002). Importance of detecting numerical versus structural chromosome aberrations. *Mutation Research* 504, 137-148.
- Kirsch-Volders, M., Vanhauwaert, A., Eichenlaub-Ritter, U, Decordier, I. (2003). Indirect mechanisms of genotoxicity. *Toxicology Letters* 140-141, 63-74.
- Knight, A., Little, S., Houck, K., Dix, D., Judson, R., Richard, A., McCarroll, N., Akerman, G., Yang, C., Birrell, L., *et al.* (2009). Evaluation of high-throughput genotoxicity assays used in profiling the US EPA ToxCast™ chemicals. *Regulatory Toxicology Pharmacology* 55, 188-199.
- Krishna, G., Urda, G., and Theiss, J. (1998). Principles and Practices of Integrating Genotoxicity Evaluation Into Routine Toxicology Studies: A Pharmaceutical Industry perspective. *Environmental and Molecular Mutagenesis* 32, 115-120.
- Ku, W., Aubrecht, J., Mauthe, R., Schiestl, R., and Fornace Jr, A. (2007a). Genetic Toxicity Assessment: Employing the Best Science for Human Safety Evaluation Part VII: Why Not Start with a Single Test: A Transformational Alternative to Genotoxicity Hazard and Risk Assessment. *Toxicological Sciences* 99, 20-25.
- Ku, W., Bigger, A., Brambilla, G., Glatt, H., Gocke, E., Guzzie, P., Hakura, A., Honma, M., Martus, H., Scott Obach, R., *et al.* (2007b). Strategy for genotoxicity testing-Metabolic considerations. *Mutation Research* 627, 59-77.
- Laingam, S., Froschio, S., and Humpage, A. (2008). Flow-cytometric analysis of *in vitro* micronucleus formation: Comparative studies with WIL2-NS human lymphoblastoid and L5178Y mouse lymphoma cells. *Mutation Research* 656, 19-26.
- Lambert, I., Singer, T., Boucher, S., and Douglas, G. (2005). Detailed review of transgenic rodent mutation assays. *Mutation Research* 590, 1-280.
- Le Hegarat, L.D., J; Josse, R; Huet, S; Lanceleur, R; Mourot, A; Poul, J; Guguen-Guillouzo, C; Guillouzo, A; Fessard, V (2010). Assessment of the genotoxic potential of indirect chemical mutagens in HepaRG cells by the comet and the cytokinesis-block micronucleus assays *Mutagenesis* 25, 555-560.
- Li, A.G., RS. Heflich, RH. Wassom JS. (1988). A review and analysis of the Chinese hamster ovary/hypoxanthine guanine phosphoribosyl transferase assay to determine the mutagenicity of chemical agents. A report of phase III of the U.S. Environmental Protection Agency Gene-Tox Program. *Mut.Res.* 196, 17-36.
- Long, L., Kirkland, D., Whitwell, J., and Halliwell, B. (2007). Different cytotoxic and clastogenic effects of epigallocatechin gallate in various cell-culture media due to variable rates of oxidation in culture media. *Mutation Research* 634, 177-183.
- Lorge, E., Hayashi, M., Albertini, S., and Kirkland, D. (2008). Comparison of different methods for an accurate assessment of cytotoxicity in the *in vitro* micronucleus test. *Mutation Research* 655, 1-3.
- [Lorge, E., Moore, MM., Clements, J., et al. \(2016\) Standardized cell sources and recommendations for good cell culture practices in genotoxicity testing, *Mutation Research/Genetic Toxicology and Environmental Mutagenesis* 809, 1-15.](#)

1670

1671 Lorge, E., Thybaud, V., Aardema, M., Oliver, J., Wakata, A., Lorenzon, G., and Marzin, D. (2006).
1672 SFTG international collaborative study on the *in vitro* micronucleus test I. General conditions and overall
1673 conclusions of the study. *Mutation Research* 607, 13-36.

1674 Lynch, A.M., Sasaki, J.C., Elespuru, R., Jacobson-Kram, D., Thybaud, V., De Boeck, M., Aardema,
1675 M.J., Aubrecht, J., Benz, R.D., Dertinger, S.D., *et al.* (2011). New and emerging technologies for genetic
1676 toxicity testing. *Environmental and Molecular Mutagenesis* 52, 205-223.

1677 [MacGregor, J.T., Frötschl, R., White, P.A., et al. \(2015a\). IWGT report on quantitative approaches to](#)
1678 [genotoxicity risk assessment I. Methods and metrics for defining exposure–response relationships and](#)
1679 [points of departure \(PoDs\). *Mutation Research/Genetic Toxicology and Environmental Mutagenesis*,](#)
1680 [783, 55-65.](#)

1681 [MacGregor, J.T., Frötschl, R., White, P.A et al. \(2015b\). IWGT report on quantitative approaches to](#)
1682 [genotoxicity risk assessment II. Use of point-of-departure \(PoD\) metrics in defining acceptable exposure](#)
1683 [limits and assessing human risk. *Mutation Research/Genetic Toxicology and Environmental*](#)
1684 [*Mutagenesis* 783, 66-78.](#)

1685 Madrigal-Bujaidar, E., Madrigal-Santillan, E., Alvarez-Gonzalez, I., Baez, R., and Marquez, P. (2008).
1686 Micronuclei Induced by Imipramine and Desipramine in Mice: A Subchronic Study. *Basic & Clinical*
1687 *Pharmacology & Toxicology*. 103, 569-573.

1688 Maierhofer, C., Jentsch, I., lederer, G.F., C., and Speicher, M. (2002). Multicolor FISH in two and three
1689 diemnsions for clastogenic analysis. *Mutagenesis* 17, 523-527.

1690 Mathews, E., Kruhlak, N., Cimino, M., Benz, R., and Contrera, J. (2006). An analysis of genetic
1691 toxicology, reproductive and developmental toxicity and carcinogenicity data I: Idenitfication of
1692 carcinogens using surrogate end points. *Regulatory Toxicology and Pharmacology* 44, 83-96.

1693 Matthews, E., Kruhlak, N., Cimino, M., Benz, R., and Contrera, J. (2006). An analysis of genetic
1694 toxicology, reproductive and developmental toxicity and carcinogenicity data: II Identification of
1695 genotoxicants, reprotoxicants, and carcinogens using in silico methods. *Regulatory Toxicology and*
1696 *Pharmacology* 44, 97-110.

1697 Mekenyan, O., Dimitrov, S., Serafimova, R., Thompson, E., Kotov, S., Dimitrova, N., and Walker, J.
1698 (2004). Identification of the structural requirements for mutagenicity by incorporating molecular
1699 flexibility and metabolic activation of chemicals I: TA100 model *Chemical Research and Toxicology*
1700 17, 753-766.

1701 Miller, J., Vlasakova, K., Glaab, W., and Skopek, T. (2005). A low volume, high-throughput forward
1702 mutation assay in *Salmonella typhimurium* based on fluorouracil resistance. *Mutation Research* 578,
1703 210-224.

1704 Mitchell, I., Lambert, T., Burden, M., Sunderland, J., Porter, R., and Carlton, J. (1995). Is Polyploidy an
1705 important genotoxic lesion? *Mutagenesis* 10, 79-83.

1706 Miura, D., Dobrovolsky, V., Kimoto, T., Kasahara, Y., and Heflich, R. (2009). Accumulation and
1707 persistence of *Pig-A* mutant peripheral red blood cells following treatment of rats with a single and split
1708 doses of *N*-ethyl-*N*-nitrosourea. . *Mutation Research* 677, 86-92.

1709 Moore, M., Honma, M., Clements, J., Bolcsfoldi, G., Burlinson, B., Cifone, M., Clarke, J., Clay, P.,
1710 Doppalapudi, R., Fellows, M., *et al.* (2007). Mouse Lymphoma thymidine kinase gene mutation assay:
1711 Meeting of the International Workshop on Genotoxicity Testing, San Francisco, 2005, recommendations
1712 for 24-h treatment. *Mutation Research* 627, 36-40.

1713 Moore, M., Honma, M., Clements, J., Bolcsfoldi, G., Cifone, M., Delongchamp, R., Fellows, M.,
1714 Gollapudi, B., Jenkinson, P., Kirby, P., *et al.* (2003). Mouse Lymphoma Thymidine Kinase Gene

DRAFT DOCUMENT FOR DISCUSSION

- 1715 Mutation Assay: International Workshop on Genotoxicity Tests Workgroup Report-Plymouth, UK 2002.
1716 Mutation Research 540, 127-140.
- 1717 Moore, M., Honma, M, Clements, J, Bolcsfoldi, G, Burlinson B, Cifone M, Clarke J, , Delongchamp R,
1718 D.R., Fellows M, Gollapudi B, Hou S, Jenkinson P, Lloyd M., Majeska J, M.B., O'Donovan M, Omori
1719 T, Riach C, San R, Stankowski LF Jr, Thakur, AK, V.G.F., Wakuri S, Yoshimura I. (2006). Mouse
1720 lymphoma thymidine kinase gene mutation assay: follow-up meeting of the International Workshop on
1721 Genotoxicity Testing--Aberdeen, Scotland, 2003. Assay acceptance criteria, positive controls, and data
1722 evaluation. Environ.Mol.Mutagen. 47, 1-5.
- ~~1723 Assay acceptance criteria, positive controls, and data evaluation. Environ.Mol.Mutagen. 47, 1-5.~~
1724 Morita, T., Miyajima, A., Hatano, A. and Honma, M. (2014). Effects of lowering the proposed top-
1725 concentration limit in an in vitro chromosomal aberration test on assay sensitivity and on the reduction
1726 of the number of false positives. Mutation Research 769,34-49.
- 1727 Morita, T., Hamada, S., Masumura, K., Wakata, A., Maniwa, J., Takasawa, H., Yasunaga, K.,
1728 Hashizume, T., and Honma, M. (2016). Evaluation of the sensitivity and specificity of in vivo erythrocyte
1729 micronucleus and transgenic rodent gene mutation tests to detect rodent carcinogens. Mutat Res Genet
1730 Toxicol Environ Mutagen 802, 1-29.
- 1731 Muller, L., Blakely, D., Dearfield, K., Galloway, S., Guzzie, P., Hayashi, M., Kasper, P., Kirkland, D.,
1732 MacGregor, J., Parry, J., *et al.* (2003). Strategy for genotoxicity and stratification of genotoxicity test
1733 results- report of initial activities of the IWGT Expert Group. Mutation Research 540, 177-181.
- 1734 Müller, L.K., P. (2000). Human biological relevance and the use of threshold-arguments in regulatory
1735 genotoxicity assessment: experience with pharmaceuticals. Mutation Research 464, 19-34.
- 1736 Mun, G., Aardema, M., Hu, T., Barnett, B., Kaluzhny, Y., Klausner, M., Karetzky, V., Dahl, E., and
1737 Curren, R. (2009). Further development of the EpiDerm™ 3D reconstructed human skin micronucleus
1738 (RSMN) assay. Mutation Research 673, 92-99.
- 1739 OECD (1997). Organisation for Economic Co-operation and Development. Ninth addendum to the
1740 OECD guidelines for the testing of chemicals. Update of Section 4, Health Effects. Revised guidelines
1741 424, 471, 473, 474, 475, 476, 483, 486, 487
- 1742 OECD (2004). OECD Series on testing and Assessment. Number 49. The report from the Expert Group
1743 on (Quantitative) Structure-Activity Relationships [(Q)SARs] on the principles for the validation of
1744 (Q)SARs. (2nd Meeting of the Ad hoc Expert group on QSARs, OECD Headquarters, 20-21 September
1745 2004. JT00176183, ENV/JM/MONO(2004)24, 17-Dec-2005.
- 1746 OECD (2009). Detailed Review Paper On Transgenic Rodent Mutation Assays, Series On Testing And
1747 Transgenic Rodent Gene Mutation Assay Draft OECD Test Guideline Sept 15 version.doc 10
1748 Assessment Number 103, OECD, Paris, July 23, 2009.
1749 [http://www.olis.oecd.org/olis/2009doc.nsf/linkto/ENV-JM-MONO\(2009\)7](http://www.olis.oecd.org/olis/2009doc.nsf/linkto/ENV-JM-MONO(2009)7).
- ~~1750 OECD (2013). OECD GUIDELINES FOR THE TESTING OF CHEMICALS Transgenic Rodent~~
~~1751 Somatic and Germ Cell Gene Mutation Assays. Available: Error! Hyperlink reference not valid.:~~
- 1752 OECD (2016a). OECD GUIDELINE FOR THE TESTING OF CHEMICALS In Vitro Mammalian Cell
1753 Micronucleus Test. Available: [https://www.oecd-ilibrary.org/docserver/9789264264861-](https://www.oecd-ilibrary.org/docserver/9789264264861-en.pdf?expires=1533801766&id=id&accname=guest&checksum=7E11CD6A97E99C8EE995DC7E46536D76)
1754 [en.pdf?expires=1533801766&id=id&accname=guest&checksum=7E11CD6A97E99C8EE995DC7E46](https://www.oecd-ilibrary.org/docserver/9789264264861-en.pdf?expires=1533801766&id=id&accname=guest&checksum=7E11CD6A97E99C8EE995DC7E46536D76)
1755 [536D76](https://www.oecd-ilibrary.org/docserver/9789264264861-en.pdf?expires=1533801766&id=id&accname=guest&checksum=7E11CD6A97E99C8EE995DC7E46536D76).
- 1756 OECD (2016b). OECD GUIDELINE FOR THE TESTING OF CHEMICALS In Vivo Mammalian
1757 Alkaline Comet Assay. Available: [https://www.oecd-ilibrary.org/docserver/9789264264885-](https://www.oecd-ilibrary.org/docserver/9789264264885-en.pdf?expires=1525089115&id=id&accname=guest&checksum=75B861F770C09914E3F613E68652F975)
1758 [en.pdf?expires=1525089115&id=id&accname=guest&checksum=75B861F770C09914E3F613E68652](https://www.oecd-ilibrary.org/docserver/9789264264885-en.pdf?expires=1525089115&id=id&accname=guest&checksum=75B861F770C09914E3F613E68652F975)
1759 [F975](https://www.oecd-ilibrary.org/docserver/9789264264885-en.pdf?expires=1525089115&id=id&accname=guest&checksum=75B861F770C09914E3F613E68652F975).OECD (2016c), Test No. 473: In Vitro Mammalian Chromosomal Aberration Test, OECD
1760 Publishing, Paris. Available: [https://www.oecd-ilibrary.org/environment/test-no-473-in-vitro-](https://www.oecd-ilibrary.org/environment/test-no-473-in-vitro-mammalian-chromosomal-aberration-test_9789264264649-en)
1761 [mammalian-chromosomal-aberration-test_9789264264649-en](https://www.oecd-ilibrary.org/environment/test-no-473-in-vitro-mammalian-chromosomal-aberration-test_9789264264649-en).

DRAFT DOCUMENT FOR DISCUSSION

- OECD (2016d) Test No. 490: In Vitro Mammalian Cell Gene Mutation Tests Using the Thymidine Kinase Gene, OECD Publishing, Paris. Available: https://www.oecd-ilibrary.org/environment/test-no-490-in-vitro-mammalian-cell-gene-mutation-tests-using-the-thymidine-kinase-gene_9789264264908-en.
- OECD (2016e), Test No. 476: In Vitro Mammalian Cell Gene Mutation Tests using the Hprt and xprt genes, OECD Publishing, Paris. Available: https://www.oecd-ilibrary.org/environment/test-no-476-in-vitro-mammalian-cell-gene-mutation-tests-using-the-hprt-and-xprt-genes_9789264264809-en.
- OECD (2020a). OECD GUIDELINE FOR THE TESTING OF CHEMICALS, OECD Publishing, Paris. Available: <http://www.oecd.org/chemicalsafety/testing/oecdguidelinesforthetestingofchemicals.htm>
- OECD (2020b). OECD GUIDELINES FOR THE TESTING OF CHEMICALS Transgenic Rodent Somatic and Germ Cell Gene Mutation Assays. Available: https://www.oecd-ilibrary.org/fr/environment/test-no-488-transgenic-rodent-somatic-and-germ-cell-gene-mutation-assays_9789264203907-en
- Ogawa, I., Furukawa, S., Abe, M., Tanaka, Y., and Hayashi, S.U., K. (2009). Multi-endpoint genotoxic assay using L5178Y ($Tk^{+/-}$ -3.7.2c) cells. *The Journal of Toxicological Sciences* 34, 547-553.
- Olaharski, A., Albertini, S., Kirchner, S., Platz, S., Uppal, H., Lin, H., and Kolaja, K. (2009). Evaluation of the GreenScreen GADD45a-GFP indicator assay with non-proprietary and proprietary compounds. *Mutation Research* 672, 10-16.
- Oliver, J., Meunier, J.-R., Awogi, T., Elhajouji, A., Ouldelhkim, M.-C., Bichet, N., Thybaud, V., Lorenzon, G., Marzin, D., and Lorge, E. (2006). SFTG international collaborative study on in vitro micronucleus test V. Using L5178Y cells. *Mutation Research* 607, 125-152.
- Pacchierotti, F., Adler, I.-D., Eichenlaub-Ritter, U., and Mailher, J.B. (2007). Gender effects on the incidence of aneuploidy in mammalian germ cells. *Environ. Res.* 104, 46-69.
- Parry, J. (2006). The use of the *in vitro* micronucleus assay to detect and assess the aneugenic activity of chemicals. *Mutation Research* 607, 5-8.
- Parry, J., Parry, E., Phrakonkham, P., and Corvi, R. (2010). Analysis of published data for top concentrations in mammalian cell genotoxicity testing. *Mutagenesis* 25, 531-538.
- Pfuhler, S. (2009). 5th International Workshop on Genotoxicity testing, August 17-19, 2009. Topic 3: In vitro test approaches with better predictivity. ICEM, Florence, August 20-25, 2009.
- Pfuhler, S., Albertini, S., Fautz, R., Herbold, B., Madle, S., Utesch, D., and Poth, A. (2007). Genetic Toxicity Assessment: Employing the Best Science for Human Safety Evaluation Part IV: Recommendation of a Working Group of the Gesellschaft fuer Umwelt-Mutationsforschung (GUM) for a Simple and Straightforward Approach to Genotoxicity Testing. *Toxicological Sciences* 97, 237-240.
- Pfuhler, S., Fellows, M., van Benthem, J., Corvi, R., Curren, R., Dearfield, K., Fowler, P., Frotschl, R., Elhajouji, A., Le Hegarat, L., *et al.* (2011). *In vitro* genotoxicity test approaches with better predictivity: Summary of an IWGT workshop. *Mutation Research* 723, 101-107.
- Pfuhler, S., Kirkland, D., Hayashi, M., Vanparys, P., Carmichael, P., Dertinger, S., Eastmond, D., Elhajouji, A., Krul, C., Rothfuss, A., *et al.* (2009). Reduction of use of animals in regulatory genotoxicity testing: Identification and implementation opportunities- Report from an ECVAM workshop. *Mutation Research* 680, 31-42.

DRAFT DOCUMENT FOR DISCUSSION

- 1804 Pfuhler, S., Kirst, A., Aardema, M., Banduhn, N., Garsten, G., Daisuke, A., Costabel-Farkas, M., Dufour,
1805 E., Fautz, R., Harvey, J., *et al.* (2010). A tiered approach to the use of alternatives to animal testing for
1806 the safety assessment of cosmetics: Genotoxicity. A COLIPA analysis.
- 1807 [Pfuhler S, Pirow R, Downs TR, Haase, A., Hewitt, N., Luch, A., Merkel, M., Petrick, C., Said, A., et al.](#)
1808 [\(2020a\). Validation of the 3D reconstructed human skin Comet assay, an animal-free alternative for](#)
1809 [following-up positive results from standard in vitro genotoxicity assays \[published online ahead of print,](#)
1810 [2020 Mar 10\]. *Mutagenesis*.](#)
- 1811 [Pfuhler, S., van Benthem, J., Curren, R., Doak, SH., Dusinska, M., Hayashi, M., Heflich, RH., Kidd, D.,](#)
1812 [Kirkland, D., Luan, Y. et al. \(2020b\). Use of in vitro 3D tissue models in genotoxicity testing: Strategic](#)
1813 [fit, validation status and way forward. Report of the working group from the 7th International Workshop](#)
1814 [on Genotoxicity Testing \(IWGT\), Mutation Research/Genetic Toxicology and Environmental](#)
1815 [Mutagenesis, Volumes 850–851.](#)
- 1816 Phelps, J., Garriott, M., and Hoffman, W. (2002). A protocol for the in vitro micronucleus test II.
1817 Contributions to the validation of a protocol suitable for regulatory submissions from an examination of
1818 10 chemicals with different mechanisms of action and different levels of activity. *Mutation Research*
1819 *521*, 103-112.
- 1820 Phillips, D., Farmer, P., Beland, F., Nath, R., Poirier, M., Reddy, M., and Turteltaub, K. (2000). Methods
1821 of DNA adduct determination and their application to testing compounds for genotoxicity. *Environ Mol*
1822 *Mutagen* *35*, 222-233.
- 1823 Pratt, I.B., T. (2003). Regulatory recognition of indirect genotoxicity mechanisms in the European Union.
1824 *Toxicology Letters* *140-141*, 53-62.
- 1825 Ponton, I., Mutch, P., Nicholls, D.J., Saad, A., Diaz Pohl, C., Young, A., Fred, C., O'Donovan, M.R.,
1826 and Aberg, P. (2013). Micronucleus induction in the bone marrow of rats by pharmacological
1827 mechanisms. II: long-acting beta-2 agonism. *Mutagenesis* *28*, 233-239.
- 1828 Ranaldi, R., Gambuti, G., Eichenlaub-Ritter, U., and Pacchierotti, F. (2008). Triclorfon effects on mouse
1829 oocytes following in vivo exposure *Mutation Research* *651*, 125-130.
- 1830 Rapp, A., Bock, C., Dittmar, H., and Greulich, K.-O. (2000). UV-A breakage sensitivity of human
1831 chromosomes as measured by COMET-FISH depends on gene density and not on chromosome size. .
1832 *Journal of Photochemistry and Photobiology B: Biology* *56*, 109-117.
- 1833 Reifferscheid, G., Arndt, C., and Schmid, C. (2005). Further Development of the β -lactamase Mutagen
1834 Assay and Evaluation by Comparison with Ames Fluctuation Tests and the umu Test. *Environmental*
1835 *and Molecular Mutagenesis* *46*, 126-139.
- 1836 Reisinger, K., Blatz, V., Brinkmann, J., Downs, T., Fischer, A., Henkler, F., Hoffmann, S., Krul, C., Liebsch,
1837 M., Luch, A., Pirow, R., Reus, A., Schulz, M., Pfuhler, S. (2018) Validation of the 3D Skin Comet assay
1838 using full thickness skin models: Transferability and reproducibility. *Mutation Research/Genetic*
1839 *Toxicology and Environmental Mutagenesis* *827*, 27-41.
- 1840 [Reus, A. A., Reisinger, K., Downs, T. R., Carr, G. J., Zeller, A., Corvi, R., Krul, C. A., &](#)
1841 [Pfuhler, S. \(2013\). Comet assay in reconstructed 3D human epidermal skin models--](#)
1842 [investigation of intra- and inter-laboratory reproducibility with coded](#)
1843 [chemicals. *Mutagenesis*, 28\(6\), 709–720.](#)
- 1844 Roithfuss, A., Steger-Hartmann, T., Heinrich, N., and Wichard, J. (2006). Conspirational Prediction of
1845 the Chromosome-Damaging Potential of Chemicals. *Chem Res Toxicol* *19*, 1313-1319.
- 1846 Rothfuss, A., Honma, M., Czich, A., Aardema, M., Burlinson, B., Galloway, S., Hamada, S., Kirkland,
1847 D., Heflich, R., Howe, J., *et al.* (2010). Improvement Of *In Vitro* Genotoxicity Assessment: Combination
1848 of Acute Tests and the Link to Standard Toxicity Testing. *Mutation Research* (accepted for publication).

- 1849 Rothfuss, A., Honma, M, Czich, A, Aardema, MJ, Burlinson, B, Galloway, S, Hamada, S, Kirkland, D,
1850 Heflich, RH, Howe, J, Nakajima, M, O'Donovan, M, Plappert-Helbig, U, Priestley, C, Recio, L, Schuler,
1851 M, Uno Y, Martus, HJ (2011). Improvement of *in vivo* genotoxicity assessment: Combination of acute
1852 tests and integration into standard toxicity testing. *Mutation Research* xx, xx.
- 1853 Roy, S., Kulkarni, R., Hewitt, N.J. and Aardema, M.J. (2016). The EpiDerm™ 3D human reconstructed
1854 skin micronucleus (RSMN) assay: Historical control data and proof of principle studies for mechanistic
1855 assay adaptations. *Mutation Research* 805, 25-37. Russo, A. (2000). *In vivo* cytogenetics in mammalian
1856 germ cells. *Mutation Research* 455, 167-189.
- 1857 Santos, S.J., Singh, N.P., and Natarajan, A.T. (1997). Fluorescence in situ hybridization with comets. .
1858 *Experimental Cell Research* 232, 407-411.
- 1859 SCCNFP (2003). The Scientific Committee on Cosmetic Products and Non-food Products intended for
1860 Consumers. Updated recommended strategy for testing hair dyes for their potential
1861 genotoxicity/mutagenicity/carcinogenicity. Available:
1862 http://ec.europa.eu/health/ph_risk/committees/sccp/documents/out224_en.pdf
- 1863 SCCS (2016). The Scientific Committee on Consumer Safety. The SCCS notes of guidance for the testing
1864 of cosmetic ingredients and their safety evaluation. Available:
1865 http://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_190.pdf [accessed Aug
1866 2018].
- 1867 Schisler, M., Gollupudi, B., and Moore, M. (2010). Evaluation of the Mouse Lymphoma Mutation Assay
1868 (MLA) Data of the U.S. National Toxicology Program (NTP) Using International Workshop on
1869 Genotoxicity Tests (IWGT) Criteria. *Environmental Molecular Mutagenesis* 51, P96.
- 1870 Serafimova, R., Todorov, M., Pavlov, T., Kotov, S., Jacob, E., Aptula, A., and Mekenyan, O. (2007).
1871 Identification of the structural requirements for mutagenicity by incorporating molecular flexibility and
1872 metabolic activation of chemicals. II. General Ames and mutagenicity model *Chemical Research and*
1873 *Toxicology* 20, 662-676.
- 1874 Shuey, D.L., Gudi, R., Krsmanovic, L., and Gerson, R.J. (2007). Evidence that oxymorphone-induced
1875 increases in micronuclei occur secondary to hyperthermia. *Toxicol Sci* 95, 369-375.
- 1876 Singer, T., Lambert, I., Williams, A., Douglas, G., and Yauk, C. (2006). Detection of induced male
1877 germline mutation: Correlations and comparisons between traditional germline mutation assays,
1878 transgenic rodent assays and expanded simple tandem repeat instability assays. *Mutation Research* 598,
1879 164-193.
- 1880 Snyder, R., and Smith, A. (2005). Computational prediction of genotoxicity: room for improvement.
1881 *Drug Discovery Today (Biosilico)* 10, 1119-1124.
- 1882 Sofuni, T., Honma, M, Hayashi, M, Shimada, H, Tanaka, N, Wakuri, S, Awogi, T, Yamamoto, KI, Nishi,
1883 Y, Nakadate, M. (1996). Detection of *in vitro* clastogens and spindle poisons by the mouse lymphoma
1884 assay using the microwell method: interim report of an international collaborative study. *Mutagenesis*
1885 11, 349-355.
- 1886 Sotomajor, R.E., and Sega, G.A. (2000). Unscheduled DNA synthesis assay in mammalian
1887 spermatogenic cells: an update. *Environ.Mol.Mutagen.* 36, 255-265.
- 1888 Spanswick, V., Hartley, J., and Hartley, J. (2010). *Methods in Molecular Biology*, volume 613, *Drug-*
1889 *DNA Interaction Protocols*, Edited KR Fox, Chapter 17 Measurement of DNA interstrand Crosslinking
1890 in Individual Cells Using the Single Cell Gel Electrophoresis (Comet) Assay. 267-282.
- 1891 Speit, G., Kojima, H., Burlinson, B., Collins, A.R., Kasper, P., Plappert-Helbig, U., Uno, Y., Vasquez,
1892 M., Beevers, C., De Boeck, M., *et al.* (2015). Critical issues with the *in vivo* comet assay: A report of the
1893 comet assay working group in the 6th International Workshop on Genotoxicity Testing (IWGT). *Mutat*
1894 *Res Genet Toxicol Environ Mutagen* 783, 6-12.

DRAFT DOCUMENT FOR DISCUSSION

- Speit, G., Vasquez, M., and Hartmann, A. (2009). The comet assay as an indicator test for germ cell genotoxicity. *Mutation Research* 681, 3-12.
- [Spiliotopoulos D., Koelbert, C. \(2020\). Assessment of the miniaturized liquid Ames microplate format \(MPF™\) for a selection of the test items from the recommended list of genotoxic and nongenotoxic chemicals. *Mutat. Res.* 856-857, 503218.](#)
- Suzuki, H., Ikeda, N., Kobayashi, K., Terashima, Y., Shimada, Y., Suzuki, T., Hagiwara, T., Hatakeyama, S., Nagaoka, K., Yoshida, J., *et al.* (2005a). Evaluation of liver and peripheral blood micronucleus assays with 9 chemicals using young rats A study by the Collaborative Study group for the Micronucleus Test (CSGMT)/ Japanese Environmental Mutagenicity Society (JEMS)-Mammalian Mutagenicity Study Group (MMS). *Mutation Research* 583, 133-145.
- [Suzuki H, Takasawa H, Hironao, S., Kazuo, T., Yukari, K., Yashui, T., Izumi, O., Tanaka, J., Imamura T., Miyazaki, A., et al. \(2009\) Evaluation of a liver micronucleus assay with 12 chemicals using young rats \(II\): a study by the Collaborative Study Group for the Micronucleus Test/Japanese Environmental Mutagen Society-Mammalian Mutagenicity Study Group. *Mutagenesis*.24\(1\):9-16.](#)
- ~~uki, H., Ikeda, N., Kobayashi, K., Terashima, Y., Shimada, Y., Suzuki, T., Hagiwara, T., Hatakeyama, S., Nagaoka, K., Yoshida, J., *et al.* (2005b). Evaluation of liver and peripheral blood micronucleus assays with 9 chemicals using young rats. A study by the Collaborative Study Group for the Micronucleus Test (CSGMT)/Japanese Environmental Mutagen Society (JEMS)-Mammalian Mutagenicity Study Group (MMS). . *Mutation Research* 583, 133-145.~~
- Takasawa H, Suzuki H, Ogawa I, Shimada, K., Kobayashi, K., Terashima Y., Matsumoto, H., Aruga, C., Oshida, K., Oht, R., et al. (2010) Evaluation of a liver micronucleus assay in young rats (III): a study using nine hepatotoxicants by the Collaborative Study Group for the Micronucleus Test (CSGMT)/Japanese Environmental Mutagen Society (JEMS)-Mammalian Mutagenicity Study Group (MMS). *Mutat Res.* 698(1-2):30-37.
- Thybaud, V., Aardema, M., Clements, J., Dearfield, K., Galloway, S., Hayashi, M., Jacobson-Kram, D., Kirkland, D., MacGregor, J., Marzin, D., *et al.* (2007). Strategy for genotoxicity testing: Hazard identification and risk assessment in relation *in vitro* testing. *Mutation Research* 627, 41-58.
- Thybaud, V., Dean, S., Nohmi, T., de Boer, J., Douglas, G., Glickman, B., Gorelick, N., Heddle, J., Heflich, R., Lambert, I., *et al.* (2003). *In vivo* transgenic mutation assays. *Mutation Research* 540, 141-151.
- Torous, D., Dertinger, S., Hall, N., and Tometsko, C. (2000). Enumeration of micronucleated reticulocytes in rat peripheral blood: a flow cytometric study. *Mutation Research* 465, 91-99.
- Trivedi, P.P., Kushwaha, S., Tripathu, D.N., and Jena, G.B. (2010). Evaluation of male germ cell toxicity in rats: Correlation between sperm head morphology and sperm comet assay. *Mut.Res.* 703, 115-121.
- Tweats, D.J., Blakey, D., Heflich, R.H., Jacobs, A., Jacobsen, S.D., Morita, T., Nohmi, T., O'Donovan, M.R., Sasaki, Y.F., Sofuni, T. and Tice, R. (2007a). Report of the IWGT working group on strategies and interpretation of regulatory *in vivo* tests. I. Increases in micronucleated bone marrow cells in rodents that do not indicate genotoxic hazards. *Mutation Research* 627, 78-91.
- Tweats, D., Blakely, D., Heflich, R., Jacobs, A., Jacobsen, S., Morita, T., Nohmi, T., O'Donovan, M., Sasaki, Y., Sofuni, T., *et al.* (2007b). Report of the IWGT working group on strategy/interpretation for regulatory *in vivo* tests. II. Identification of *in vivo*-only positive compounds in the bone marrow micronucleus test. *Mutation Research* 627, 92-105.
- UKEMS. (1989). Statistical evaluation of mutagenicity test data. UKEMS sub-committee on guidelines for mutagenicity testing. Report . Part III. Editor Kirkland DJ. Published Cambridge University Press.

- 1942 Uno, Y., Kojima, H., and Hayashi, M. (2015a). The JaCVAM-organized international validation study
1943 of the *in vivo* rodent alkaline comet assay. *Mutat Res Genet Toxicol Environ Mutagen* 786-788, 2.
- 1944 [Uno, Y., Morita, T., Luijten, M., Beevers, C., Hamada, S., Itoh, S., Ohyama, W. and Takasawa, H.](#)
1945 [\(2015b\). Recommended protocols for the liver micronucleus test: Report of the IWGT working group.](#)
1946 [Mutat Res Genet Toxicol Environ Mutagen. 783,13-18.](#)
- 1947 Vasquez, M. (2010). Combining the *in vivo* comet and micronucleus assays: a practical approach to
1948 genotoxicity testing and data interpretation. *Mutagenesis* 25, 187-199.
- 1949 Vogt, E., Kirsch-Volders, M., Parry, J., and Eichenlaub-Ritter, U. (2008). Spindle formation,
1950 chromosome segregation and the spindle checkpoint in mammalian oocytes and susceptibility to meiotic
1951 error. *Mut.Res.* 651, 14-29.
- 1952 Wakata, A., Matsuoka, A., Yamakage, K., Yoshida, J., Kubo, K., Kobayashi, K., Senjyu, N., Itoh, S.,
1953 Miyajima, H., Hamada, S., *et al.* (2006). SFTG international collaborative study on *in vitro* micronucleus
1954 test IV. Using CHL cells. *Mutation Research* 607, 88-124.
- 1955 Wakata, A., Miyamae, Y., Sato, S., Suzuki, T., Morita, T., Asano, N., Awogi, T., Kondo, K., and Hayashi,
1956 M. (1998). Evaluation of the Rat Micronucleus Test with Bone Marrow and peripheral Blood: Summary
1957 of the 9th Collaborative Study by the CSGMT/JEMS.MMS. *Environ Mol Mutagen* 32, 84-100.
- 1958 Wang, J., Sawyer, J., Chen, L., Chen, T., Honma, M., Mei, N., and Moore, M. (2009). The Mouse
1959 Lymphoma Assay Detects Recombination, Deletion and Aneuploidy. *Toxicological Sciences* 109, 96-
1960 105.
- 1961 Westerink, M., Stevenson, J., Horbach, G., Saito, Y., and Schoonen, W. (2010). The development of
1962 RAD51C, Cystatin A, p53 and Nrf2 luciferase-reported assays in metabolically competent HepG2 cells
1963 for the assessment of mechanism-based genotoxicity and oxidative stress in early research phase of drug
1964 development. *Mutation Research* 696, 21-40.
- 1965 Westerink, W., Stevenson, J., Lauwers, A., Griffioen, G., Horbach, G., and Schoonen, W. (2009).
1966 Evaluation of the Vitotox™ and RadarScreen assays for rapid assessment of genotoxicity in the early
1967 research phase of drug development. *Mutation Research* 676, 113-130.
- 1968 Witt, I., Plappert, U., de Wall, H., and Hartmann, A. (2007). Genetic Toxicity Assessment: Employing
1969 the Best Science for Human Safety Evaluation part III. The Comet Assay as an Alternative to *In vitro*
1970 Clastogenicity Tests for Early Drug Candidate Selection. *Toxicological Sciences* 97, 21-26.
- 1971 Witt, K., Hughes, L., Burka, L., McFee, A., Mathews, J., Black, S., and Bishop, J. (2003). Mouse bone
1972 marrow micronucleus test results do not predict the germ cell mutagenicity of N-
1973 hydroymethylacrylamide in the mouse dominant lethal assay. *Environ Mol Mutagen* 41, 111-120.
- 1974 Witt, K., Knapton, A., Wehr, C., Hook, G., Mirsalis, J., Shelby, M., and MacGregor, J. (2000).
1975 Micronucleated Erythrocyte Frequency in Peripheral Blood of B6C3F₁ Mice from Short-Term,
1976 prechronic, and Chronic Studies of the NTP Carcinogenesis Bioassay Program. *Environmental and*
1977 *Molecular Mutagenesis* 36, 163-194.
- 1978 Worth, A., Bassan, A., Gallegos, A., Netzeva, T., Patlewicz, G., Pavan, M., Tsakovska, I., and Vracko,
1979 M. (2005). The Characterisation of (Quantitative) Structure-Activity Relationships: Preliminary
1980 Guidance. Report from European Commission Joint Research Centre, EUR 21866 EN, 2005.
- 1981 Yauk, C.L., Aardema, M.J., Benthem, J., Bishop, J.B., Dearfield, K.L., DeMarini, D.M., Dubrova, Y.E.,
1982 Honma, M., Lupski, J.R., Marchetti, F., *et al.* (2015). Approaches for identifying germ cell mutagens:
1983 Report of the 2013 IWGT workshop on germ cell assays(). *Mutat Res Genet Toxicol Environ Mutagen*
1984 783, 36-54.
- 1985 Yin, H., Cukrcam, S., Betzendahl, I., Adler, I.-D., and Eichenlaub-Ritter, U. (1998). Trichlorfon
1986 exposure, spindle aberrations and nondisjunction in mammalian oocytes. *Chromosoma* 107, 514-522.

DRAFT DOCUMENT FOR DISCUSSION

1987 Zeiger, E., Ashby, J., Bakale, G., Enslein, K., Klopman, G., and Rosenkranz, H. (1996). Prediction of
1988 Salmonella mutagenicity. . *Mutagenesis* *11*, 471-484.

1989

1990

GLOSSARY

Adduct: A chemical grouping which is covalently bound to a large molecule such as DNA or protein.

Alkylating agents: Chemicals which leave an alkyl group covalently bound to biologically important molecules such as proteins and nucleic acids (see adduct). Many alkylating agents are mutagenic, carcinogenic and immunosuppressive.

Ames test: *In vitro* assay for bacterial gene mutations using strains of *Salmonella typhimurium* developed by Ames and his colleagues.

Aneugenic: Inducing aneuploidy (qv).

Aneuploidy: The circumstances in which the total number of chromosomes within a cell is not an exact multiple of the normal haploid (see 'polyploidy') number. Chromosomes may be lost or gained during cell division.

Apoptosis: A form of active cell death resulting in fragmentation of the cell into membrane-bound fragments (apoptotic bodies). These are usually rapidly removed *in vivo* by engulfment by phagocytic cells. Apoptosis can occur normally during development, but is often triggered by toxic stimuli.

Cancer: Synonym for a malignant neoplasm – that is, a tumour (qv) that grows progressively, invades local tissues and spreads to distant sites (see also tumour).

Carcinogenesis: The origin, causation and development of tumours (qv). The term applies to benign as well as malignant neoplasms and not just to carcinomas

Carcinogenicity bioassay: Tests carried out in laboratory animals, usually rats and mice, to determine whether a chemical is carcinogenic. The test material is given throughout life to groups of animals at different dose levels.

Carcinogens: The causal agents which induce tumours. They include external factors (chemicals, physical agents, viruses) and internal factors such as hormones. Chemical carcinogens are structurally diverse and include naturally-occurring chemicals as well as synthetic compounds. An important distinction can be drawn between genotoxic (qv) carcinogens which have been shown to react with and mutate DNA, and non-genotoxic carcinogens which act through other mechanisms. The activity of genotoxic carcinogens can often be predicted from their chemical structure - either of the parent compound or of active metabolites (qv). Most chemical carcinogens exert their effects after prolonged exposure, show a dose-response relationship and tend to act on a limited range of susceptible target tissues. Carcinogens are sometimes species or sex-

specific and the term should be qualified by the appropriate descriptive adjectives to aid clarity. Several different chemical and other carcinogens may interact, and constitutional factors (genetic susceptibility, hormonal status) may also contribute, emphasising the multifactorial nature of the carcinogenic process.

Chromosomal aberrations: Collective term of particular types of chromosome damage induced after exposure to exogenous chemical or physical agents which damage the DNA. (see clastogen).

Chromosome: In simple prokaryotic organisms, such as bacteria and most viruses, the chromosome consists of a single circular molecule of DNA containing the entire genetic material of the cell. In eukaryotic cells, the chromosomes are thread-like structures, composed mainly of DNA and protein, which are present within the nuclei of every cell. They occur in pairs, the numbers varying from one to more than 100 per nucleus in different species. Normal somatic cells in humans have 23 pairs of chromosomes, each consisting of linear sequences of DNA which are known as genes.

Clastogen: An agent that produces chromosome breaks and other structural aberrations such as translocations. Clastogens may be viruses or physical agents as well as chemicals. Clastogenic events play an important part in the development of some tumours.

Cytogenetic: Concerning chromosomes, their origin, structure and function.

Cytochrome P450 (CYP): An extensive family of haem-containing proteins involved in enzymic oxidation of a wide range of endogenous and xenobiotic (qv) chemicals and their conversion to forms that may be more easily excreted. In some cases the metabolites produced may be reactive and may have increased toxicity. In other cases the chemicals may be natural precursors of hormones (e.g. steroids).

DNA Strand Breakage; A break in double-stranded DNA in which one or both of the two strands have been cleaved; both strands have not separated from each other.

DNA Strand Break Assay (Comet assay): Alkaline treatment converts certain types of DNA lesions into strand breaks that can be detected by the alkaline elution technique or by measuring migration rate through a filter, or by the single gel electrophoresis or Comet assay in which cells embedded in a thin layer of gel on a microscope slides are subjected to electric current causing shorter pieces of DNA to migrate out of the nucleus into a Comet tail. The extent of DNA migration is measured visually under the microscope on stained cells.

DRAFT DOCUMENT FOR DISCUSSION

Erythrocyte: red blood cell; corpuscle; one of the formed cells in peripheral blood. Normally, in humans, the mature form is a non-nucleated, yellowish, biconcave disk, containing haemoglobin and transporting oxygen. Normochromic erythrocyte; one of normal colour with a normal concentration of haemoglobin. Polychromatic erythrocyte; one that, on staining, shows shades of blue combined with tinges of pink indicative of an immature erythrocyte.

Eukaryotes; A class of organisms, which in contrast to prokaryotes (e.g. bacteria), comprise cells which have a nucleus in which DNA is organised into characteristic sets of chromosomes. This includes all plants and fungi except the blue-green algae and all animals.

Fluorescent in situ hybridization (FISH) A technique in which a chemically modified DNA (or RNA) probe is hybridized with target DNA, usually present as a chromosome preparation on a microscopic slide. The chemical modification can be visualized using a fluorescent microscope either directly when the modification involves use of a fluorescent dye or indirectly with the use of a fluorescently labelled affinity reagent (e.g. antibody or avidin). Depending upon the type of probe used, this approach can be used to precisely map genes to a specific region of a chromosome in a prepared karyotype, enumerate chromosomes, or detect chromosomal deletions, translocations, or gene amplifications in cancer cells.

Gametogenesis is a process by which diploid or haploid precursor cells undergo cell division and differentiation to form mature haploid gametes. Depending on the biological life cycle of the organism, gametogenesis occurs by meiotic division of diploid gametocytes into various gametes or by mitotic division of haploid gametogenous cells.

Genome: All the genetic material in the chromosomes of a particular organism; its size is generally given as its total number of base pairs.

Genotoxic: The ability of a chemical to cause DNA damage, either directly or after metabolic activation (see also carcinogens).

Genotype: The particular genetic pattern seen in the DNA of an individual. 'Genotype' is usually used to refer to the particular pair of alleles that an individual possesses at a certain location in the genome. Compare this with phenotype.

Germ cell: A biological cell that gives rise to the gametes of an organism that reproduces sexually. The cells undergo mitotic and meiotic cell division in the gonads followed by cellular differentiation into mature gametes, either oocytes or sperm.

Heritable translocation test A test that detects heritable structural chromosome changes (i.e. translocations) in mammalian germ cells as recovered in first-generation progeny.

Historical negative control data: In the context of the COM guidance on genotoxicity testing, this term refers to information on the background genotoxicity or mutagenicity data for a particular assay from a particular laboratory. Historical control data should be reported as the mean and confidence intervals for the genotoxicity or mutagenicity indices investigated.

***In vitro* chromosomal aberration assay:** An assay where cultured cell lines or human lymphocytes are incubated with test chemical. At a predetermined time, cells are arrested in metaphase, harvested and stained, and the metaphase spreads are then analysed microscopically for the presence of chromosome aberrations.

Kinetochores is the protein structure which is present on chromosomes where the spindle fibers attach during division to pull the chromosomes apart. The kinetochore forms in eukaryotes and assembles on the centromere and links the chromosome to microtubule polymers from the mitotic spindle during mitosis and meiosis. The kinetochore contains two regions: an inner kinetochore, which is tightly associated with the centromere DNA; and an outer kinetochore, which interacts with microtubules.

Kinetochores staining An immunochemical technique used to detect the presence of centromeric kinetochore proteins in MN and to identify the origin of MN. In all but a few cases, the presence of kinetochore in a micronucleus indicates that it was formed by loss of an entire chromosome, whereas a micronucleus that lacks a kinetochore originated from an acentric chromosome fragment.

Maximum Tolerated Dose; The highest dose of a chemical that can be given without causing serious weight loss (>10%) or other signs of toxicity^[DPL83].

Metabolic activation: Metabolism of a compound leading to an increase in its activity, whether beneficial (e.g. activation of a pro-drug) or deleterious (e.g. activation to a toxic metabolite).

Metabolic activation system: A cell-free preparation (e.g. from the livers of rats pre-treated with an inducing agent added to *in vitro* tests to mimic the metabolic activation typical of mammals.

Metabolism: Chemical modification of a compound by enzymes within the body, for example by reactions such as hydroxylation (see cytochrome P450), epoxidation or

conjugation. Metabolism may result in activation, inactivation, accumulation or excretion of the compound.

Metabolite: Product formed by metabolism of a compound.

Micronuclei: Isolated or broken chromosome fragments which are not expelled when the nucleus is lost during cell division, but remain in the body of the cell forming MN. Centromere positive MN contain DNA and/or protein material derived from the centromere. The presence of centromere positive MN following exposure to chemicals *in vitro* or *in vivo* can be used to evaluate the aneugenic (qv) potential of chemicals.

Micronucleus test: See Micronuclei.

Mitogen: A stimulus which provokes cell division in somatic cells.

Mitosis^[DPL84]: The type of cell division which occurs in somatic cells when they proliferate. Each daughter cell has the same complement of chromosomes as the parent cell.

Mode of Genotoxic Action (MoGAMoA): The mode of action of a ^[DPL85]genotoxicant refers to the underlying events involved in the process whereby the chemical induces genotoxic effects. In order for a specific mode of action to be supported there needs to be evidence from robust mechanistic data to establish a biologically plausible explanation. Mode of genotoxic action should be distinguished from the term mechanism of action. The latter relates to having sufficient understanding of the molecular basis of the chemical genotoxicity to establish causality. Thus mechanism of action is at the other end of a continuum from little or no evidence of mode of genotoxic action to scientific proof of mechanism of action.

Mouse lymphoma assay: An *in vitro* assay for gene mutation in mammalian cells using a mouse lymphoma cell line L5178Y, which is heterozygous for the gene (carries only one functional gene rather than a pair) for the enzyme thymidine kinase (TK^{+/-}). Mutation ^[DPL86]~~inef~~ that single gene is measured by resistance to toxic trifluorothymidine. Mutant cells produce two forms of colony - large, which represent mutations within the gene and small, which represent large genetic changes in the chromosome such as chromosome aberrations. Thus this assay can provide additional information about the type of mutation which has occurred if colony size is ^[DPL87]scored.

Mutation: A permanent change in the amount or structure of the genetic material in an organism or cell, which ^[DPL88]may or may not ~~can~~ result in a change in phenotypic characteristics. The alteration may involve a single gene, a block of genes, or a whole chromosome. Mutations involving single genes may be a consequence of effects on

single DNA bases (point mutations) or of large changes, including deletions, within the gene. Changes involving whole chromosomes may be numerical or structural. A mutation in the germ cells of sexually reproducing organisms may be transmitted to the offspring, whereas a mutation that occurs in somatic cells may be transferred only to descendent daughter cells.

Mutagenic end-points: these comprise of three levels of genetic change, namely gene mutation, clastogenicity and aneuploidy

No observable effect concentration (NOEC): the highest administered concentration at which no adverse effect or specific genotoxic effect is seen

Pharmacokinetics^[DPL89]:

Phenotype: The observable physical, biochemical and physiological characteristics of a cell, tissue, organ or individual, as determined by its genotype and the environment in which it develops.

Polyploidy: Numerical deviation of the modal number of chromosomes in a cell, with approximately whole multiples of the haploid number. Endoreduplication is a morphological form of polyploidy in which chromosome pairs are associated at metaphase as diplochromosomes.

32P-postlabelling: A sensitive experimental method designed to measure low levels of DNA adducts induced by chemical treatment.

Prokaryotes: The simplest living organisms namely viruses, bacteria and some blue green algae. The genetic material in bacteria is arranged into one chromosomal complex consisting of a single circular molecule of DNA (or RNA in some viruses). They lack an organised nucleus. Mitosis and meiosis do not occur, although nucleotide polymerisation replication takes place and division and multiplication follow.

Quantitative Structure Activity Relationships (QSARs):

Recombination: Breakage of DNA structure usually during meiosis^[DPL90] with balanced or unbalanced rejoining of DNA

S9: metabolic activation system (qv) comprising ~~of~~ the post-mitochondrial supernatant (S9) from the homogenised livers of rats treated with P450 dependent drug-metabolizing enzyme inducers such as Arochlor 1254 or phenobarbitone/ β -naphthoflavone. S9 is combined with a mix of co-factors which optimize the activity of the mixed function oxidases and form a NADPH generating system which has the capacity to metabolise chemicals *in vitro*.

Sensitivity: In the context of the COM guidance on a strategy for genotoxicity testing, the correct identification of [known](#) rodent carcinogens or *in vivo* genotoxins using genotoxicity (mutagenicity) assays based on a defined set of carcinogenicity data (e.g. Gold Carcinogenicity Potency database)

Screening test; High-Throughput [DPL91](#) [DK92](#) procedures designed to provide rapid information on toxicological end points for a large number of compounds

Specificity: In the context of the COM guidance on a strategy for genotoxicity testing, the correct prediction of [known](#) non-carcinogens as assessed in rodent carcinogenicity bioassays using genotoxicity (mutagenicity) assays based on a defined set of carcinogenicity data (e.g. Gold Carcinogenicity Potency database).

Specific locus test: A technique used to detect recessive induced mutations in diploid organisms; a strain that carries several known recessive mutants in a homozygous condition is crossed with a non mutant strain that has been treated to induce mutations in its germ cells; induced recessive mutations allelic with those of the test strain will be expressed in the progeny.

Spindle apparatus: In cell biology, the spindle apparatus is the structure that separates the chromosomes into the daughter cells during cell division. It is part of the cytoskeleton in eukaryotic cells. It is also referred to as the mitotic spindle during mitosis and the meiotic spindle during meiosis.

Structure Activity Relationships (SARs): the relationship between chemical structure and genotoxic effect based on predictions using computerised models (also Quantitative Structure Activity Relationships [q.v.](#))

Test chemical: A chemical element and its compounds in the natural state or obtained by any manufacturing process, including any additive necessary to preserve its stability and any impurity deriving from the process used, but excluding any solvent which may be separated without affecting the stability of the chemical or changing its composition.

Threshold: Dose or exposure concentration below which an effect is not expected [DPL93](#).

Topoisomerases: Enzymes which catalyze and guide the [unknotting](#) [DPL94](#) [DK95](#) of DNA by creating transient breaks in the DNA using a conserved tyrosine as the catalytic residue. In so-called circular DNA, in which double helical DNA is bent around and joined in a circle, the two strands are topologically linked, or knotted. Topoisomerase I solves the problem caused by tension generated by

winding/unwinding of DNA. It wraps around DNA and makes a cut permitting the helix to spin. Once DNA is relaxed, topoisomerase reconnects broken strands

Toxicogenomics: A ~~new~~ scientific subdiscipline that combines the ~~emerging~~ technologies of genomics and bioinformatics to identify and characterise mechanisms of action of known and suspected toxicants. Currently, the ~~main~~~~premier~~ toxicogenomic tools are the DNA microarray and the DNA chip, which are used for the simultaneous monitoring of expression levels of hundreds to thousands of genes.

Toxicokinetics: The description of the fate of chemicals in the body, including a mathematical account of their absorption, distribution, metabolism and excretion. (see pharmacokinetics)

Transgenic: Genetically modified to contain genetic material from another species (see also genetically modified organism).

Transgenic rodent gene mutation models: Animals which have extra (exogenous) fragments of DNA incorporated into their genomes. This includes transgenic mice containing reporter genes^[DPL96] to assess *in-vivo* mutagenicity in recoverable bacterial gene (*lacZ* or *lac I*). DNA can be isolated from a wide range of tissues following exposure to a test chemical and the genes assessed for induced mutations.

Translation: In molecular biology, the process during which the information in mRNA molecules is used to construct proteins^[DPL97].

Tumour (Synonym - neoplasm): A mass of abnormal, disorganised cells, arising from pre-existing tissue, which are characterised by excessive and uncoordinated proliferation and by abnormal differentiation. **Benign** tumours show a close morphological resemblance to their tissue of origin; grow in a slow expansile fashion; and form circumscribed and (usually) encapsulated masses. They may stop growing and they may regress. Benign tumours do not infiltrate through local tissues and they do not metastasise. They are rarely fatal. **Malignant tumours** (synonym - cancer) resemble their parent tissues less closely and are composed of increasingly abnormal cells in terms of their form and function. Well differentiated examples still retain recognisable features of their tissue of origin but these characteristics are progressively lost in moderately and poorly differentiated malignancies: undifferentiated or anaplastic tumours are composed of cells which resemble no known normal tissue. Most malignant tumours grow rapidly, spread progressively through adjacent tissues and metastasise to distant sites. Tumours are conventionally classified according to the anatomical site of the primary tumour and its microscopical appearance, rather than by cause.

DRAFT DOCUMENT FOR DISCUSSION

Unscheduled DNA Synthesis (UDS): DNA synthesis that occurs at some stage in the cell cycle other than the S period (the normal or 'scheduled' DNA synthesis period), in response to DNA damage. It is usually associated with DNA repair.

Weight of Evidence A quantitative ranking of evidence, or the qualitative appraisal of many different forms of evidence (e.g toxicological or genotoxicity data) to arrive at a conclusion regarding potential hazard (such as mutagenicity). [RB98]

DRAFT DOCUMENT FOR DISCUSSION

2266 **Annex 1** [DPL99]

2267 **Tabulation** [OS100][OS101] of Genotoxicity Tests (in Stages 1 and 2) and
 2268 Mutagenic/Genotoxicity End Points Detected.

Genotoxicity test	Mutagenic/genotoxicity end point detected	Comments
<i>In vitro</i> assays		
Ames	Gene mutation	Responds to wide range of DNA reactive mutagens when full set of <i>S. typhimurium</i> tester strains and <i>E. coli</i> with appropriate exogenous metabolic activation used.
Micronucleus test	Clastogenicity, aneuploidy	Centromere or kinetochore stains, with pancentromeric or chromosome specific centromeric probes using fluorescence in situ hybridisation (FISH) are required <u>to distinguish between</u> for <u>aneuploidy and clastogenicity</u>
Chromosomal aberrations	Clastogenicity, aneuploidy	Indications of aneuploidy from induction of polyploidy or increased mitotic index, but the use of chromosome specific centromeric probes fluorescence in situ hybridisation (FISH) required to assess the potential for aneuploidy. Very similar assay performance compared with micronucleus test
Mouse Lymphoma Assay	Gene mutation, clastogenicity	Distribution of large and small colony mutants can give information on induction of gene mutations versus clastogenicity. No convincing evidence that MLA can detect aneuploidy consistently.
Comet assay	DNA strand breaks and alkali labile sites	Can respond to a wide range of gene mutagens and clastogens but gives no information about modes of mutagenic action.
<u>Pig-a gene mutation assay</u>		
<i>In vivo</i> assays		
Rodent Bone Marrow/peripheral blood micronucleus assay	Clastogenicity, aneuploidy	A wide range of structurally diverse clastogens <u>and aneugens</u> have been detected. <u>Distinguishing between clastogenic and aneugenic MoAs c</u> Can also be used to investigate <u>aneuploidy</u> by use of centromere or kinetochore probes. .
Rodent transgenic mutation assay	Gene mutations	Valuable for the investigation of gene mutation in a wide range of tissues including germ cells and particularly to confirm gene mutation as a mode of action.

DRAFT DOCUMENT FOR DISCUSSION

Rodent Comet assay	DNA strand breaks, alkali labile sites	Can respond to a wide range of gene mutagens and clastogens but gives no information about modes of mutagenic action. Does not detect aneugens . Valuable for detection of DNA damage in a wide range of tissues, but the standard alkaline assay not validated for mature sperm .
Rodent Liver UDS	Unscheduled DNA synthesis	Endpoint measured is indicative of DNA damage and subsequent repair in liver cells, but now considered not as sensitive as other <i>in vivo</i> assays .
Pig-a gene mutation assay	Gene mutations	Endpoint measured is a reporter of gene mutation in rodents, but currently only extensively validated in blood cells.

2269
2270

